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ABSTRACT 
 
The radical SAM (S-adenosylmethionine) superfamily consists of a diverse set of enzymes 
which use [4Fe-4S] and SAM to initiate radical transformations. These diverse enzymes undergo 
a common series of steps where SAM is cleaved to yield methionine and a 5’-deoxyadenosyl 
radical intermediate (5’-dA•), which usually abstracts a hydrogen atom from the substrate. This 
study characterizes unresolved biochemical functions of two radical SAM enzymes: Elp3 and 
viperin. 
The eukaryotic Elongator complex is a large protein complex consisting of six Elongator 
proteins (Elp1-Elp6) and has been associated with several cellular processes and neurological 
diseases in humans. Of the six subunits, Elp3 is considered the catalytic subunit with two putative 
enzymatic activities: acetyltransferase activity for histone acetylation and radical SAM dependent 
activity for the modification of uridine at the wobble position (U34) of cytoplasmic tRNAs. The 
main biochemical function responsible for the many biological roles of the Elongator complex 
remains controversial. Accumulating evidence in the literature indicates that tRNA U34 
modification plays a more prominent role. This modification takes place in approximately 25% of 
cytoplasmic tRNAs in eukaryotic organisms.  In contrast, mitochondrial and bacterial tRNAs 
experience a different U34 modification, carried out by the MnmE-MnmG heterotetramer.   
 Bioinformatics analysis has shown that Elp3 is the only subunit that is present in most 
archaea, a few bacteria and two viruses.  Furthermore, the genes encoding MnmE-MnmG are 
absent in these organisms.  This indicates that the tRNA U34 modification found in archaeal and 
bacterial species (with Elp3) is likely the same as the one found in cytoplasmic tRNAs of 
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eukaryotes. Since these species do not have Elp1-2 or Elp4-6, we further propose that Elp3 alone 
performs the modification reaction.  
 Following chemical reconstitution of the [4Fe-4S] in Elp3 from Methanocaldococcus 
infernus (MinElp3), the modification reaction was successfully reconstituted inside an anaerobic 
chamber using synthetic tRNA. The modified base was identified as cm5U by RP-HPLC and LC-
MS. Analysis of 5’-dA generated in the presence of deuterated substrates indicated that 5’-dA• 
abstracts a hydrogen atom from acetyl-CoA. 
To investigate the in vivo U34 modification, total tRNAs and tRNAArg were isolated from 
yeast, Methanococcus maripaludis (Euryarchaeota) and Sulfolobus acidocaldarius 
(Crenarchaeota). Neither cm5U nor mcm5U/ncm5U (modification in eukarya) was detected in the 
archaea; however, two new substances (549 Da and 454 Da) were detected. Further analysis is 
required to determine if these substances are the result of a secondary reaction on cm5U.  
The SAM domain of Elp3 contains the characteristic CX4CX2C motif which binds [4Fe-
4S]. To aid in purification and crystallization, the cysteine residues in the motif were mutated to 
serine residues. Crystals were obtained from the (6xHis)-MinElp3 C95S/C98S mutant. Also, using 
the optimized crystallization conditions, small crystals of wild-type MinElp3 were obtained. 
The functional characterization of Elp3 reported in our publication, along with the evidence 
that the Elongator complex is mainly present in the cytoplasm, suggests that tRNA U34 
modification is the ancient and primary biological function of the Elongator complex. 
The first response to viral infection in mammalian cells is the induction of the interferon 
system, which activates IFN-stimulated genes (ISGs) to inhibit various stages of viral replication. 
Viperin (for virus inhibitory protein, endoplasmic reticulum associated, interferon inducible) is 
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one of the ISGs which has antiviral activity against a wide range of RNA and DNA viruses, 
however the molecular mechanism of viral inhibition remains unknown.  
Our studies indicate that the 5’-dA• generated by the recombinant viperin from 
Methanofollis liminatans (archaea), Trichoderma virens (fungi) and human adds to the carbon-
carbon double bond of isopentenyl pyrophosphate (IPP) in vitro, resulting in the formation of a 
new compound 4-adenosyl isopentenyl pyrophosphate (AIPP). The crystal structure of the 
Trichoderma virens viperin revealed that the enzyme forms a central channel, where the substrate 
IPP and cofactor SAM meet. The studies suggest a mechanism of viperin inhibiting viral infection 
by depleting IPP, resulting in reduction of downstream biological processes such as cholesterol 
biosynthesis and protein prenylation. In addition, AIPP might also contribute to viral inhibition by 
potentially acting as a signaling molecule or an inhibitor of a yet to be identified target participating 
in anti-viral activities. 
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CHAPTER 1: INTRODUCTION TO RADICAL SAM ENZYMES ELP3 AND VIPERIN 
 
1.1. Introduction  
 
Radical SAM Enzymes  
In contrast to biochemical reactions involving paired electron species, several examples of 
enzymatic reactions involving organic radical intermediates have emerged including cytochrome 
P450, methane monooxygenase and the adenosylcobalamin (B12) enzymes (1-3). Enzymes utilize 
radical mechanisms instead of polar mechanisms to catalyze difficult reactions – for example, the 
abstraction of a hydrogen atom from an unactivated C-H bond. The radical S-adenosylmethionine 
(SAM) superfamily consists of a diverse set of enzymes which use SAM and [4Fe–4S] to initiate 
radical based reactions (4). Central to each of these diverse reactions are a common series of steps 
which results in the production of a 5’-deoxyadenosyl radical intermediate (5’-dA•) (Fig 1.1), 
which can abstract a H atom from the substrate.  
Members of this superfamily have a characteristic CX3CX2C motif, although there are 
some variations in the number of residues in between the cysteine resides (Fig. 7.1). The cysteine 
residues coordinate three of the four irons of [4Fe–4S]. First, SAM binds the [4Fe–4S]2+ via the 
α-carboxyl and α-amino groups of the methionine. Next, an electron is transferred from an electron 
donor to the cluster to reduce it to the [4Fe–4S]1+ state. Flavodoxin or other single electron donors 
are used in vivo and reductants like dithionite or photoreduced 5-deazariboflavin are used in vitro. 
Next, electron transfer from [4Fe–4S]1+ to SAM promotes homolytic cleavage of the S-C5’ bond 
of SAM resulting in methionine bound to [4Fe–4S]2+ and a 5′-deoxyadenosyl radical (5’-dA•) 
intermediate. This highly reactive 5’-dA• can then abstract a H atom from the substrate to generate 
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5′-deoxyadenosine (5’-dA) and a substrate radical (5).  For glycyl radical enzyme activating 
enzymes, this is the end of the reaction (6). For some enzymes like the lysine 2,3-aminomutase, 
the product radical can abstract a H atom from the 5’-dA to regenerate  5’-dA, which then combines 
with methionine to re-form SAM (7). However, in most cases studied so far, the number of SAM 
molecules is equal to the number of H atoms that are abstracted to form a product. This thesis 
explores the biochemical and structural features of two radical SAM enzymes: Elp3 and viperin.  
 
Radical SAM enzyme: Elp3 
Discovery of the Elongator Complex 
The Elongator Complex was initially discovered as an assembly that co-purified with the 
elongating form of RNA Polymerase II in Saccharomyces cerevisiae. The association of this 
complex was dependent on the hyperphosphorylated state of RNA Polymerase II carboxy-terminal 
domain (CTD). The initial purification, under high salt conditions, revealed the presence of three 
subunits, named Elp1 (Elongator protein 1) (150 kDa), Elp2 (90 kDa) and Elp3 (50 kDa) (8).  A 
subsequent study demonstrated that the Elongator complex consists of two subcomplexes: one 
composed of Elp1-3 and the other composed of Elp4 (50 kDa), Elp5 (38 kDa) and Elp6 (31kDa) 
(Fig 1.2). Gene expression profiling indicated that all six subunits are likely to function together 
in vivo (9).  
 
The Elongator Complex in eukaryotes 
Of the six subunits, Elp3 is considered the catalytic subunit and this is consistent with the 
unusually high degree of conservation of Elp3 compared to the other subunits in eukaryotes (Fig. 
1.2C). Elp3 contains two putative enzymatic domains: a radical SAM domain near the N-terminus 
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(Fig. 1.2A, orange) (10) and a histone acetyltransferase (HAT) domain near the C-terminus (Fig. 
1.2A, red) (11). The N-terminal domain (Fig 1.2A, blue) is the least conserved and is rich in lysines 
are arginines. Lastly, the region connecting the radical SAM and HAT domain is also highly 
conserved, but its function is unknown (Fig. 1.2A, cyan). Elp1 and Elp2 are not predicted to have 
any enzymatic activities; however, they have several WD40 domains which may play the role of 
scaffolding proteins. The crystal structure of Elp456 was recently solved and was shown to have 
a hetero-hexameric RecA-like ATPase structure (Chapter 5).   
 
Controversy regarding the main cellular role of the Elongtaor Complex 
Since its discovery, there has been controversy regarding the main cellular role of the 
Elongator Complex. It has been associated with several cellular defects include those involving 
transcriptional activation (8), exocytosis (12), cell migration regulation (13), motor neuron 
degeneration (14), paternal genome demethylation (15), DNA damage response (16) and cell cycle 
regulation (13). The initial study indicated that the elp1∆ cells exhibited slow growth when 
introduced to new growth conditions, indicating a defect in transcription and nuclear localization 
of the complex. Furthermore, a general role in elongation can be attributed to its stoichiometric 
distribution with RNA Polymerase II and the fact that Elp3 has motifs characteristic of the GCN5 
family of histone acetyl transferases (8,17). A subsequent study demonstrated that Elp3, which is 
highly conserved in eukaryotes, was able to acetylate all four core histones on their amino-terminal 
tails in vitro (18). Mutations of specific residues critical for HAT activity significantly altered 
transcriptional activity (17). Furthermore, the HAT activity on H3 and H4 histones was 
demonstrated in vivo using chromatin immunoprecipitation. While Elp3 had a strong preference 
for H3, weak acetylation was also detected on H4. Even though Elp3 is part of the larger sub-
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complex (Elp1-3), the smaller sub-complex was also required for the HAT activity of the holo-
Elongator (19). Together, this data suggested that the main role of the Elongator Complex was in 
assisting in transcriptional elongation by acetylating nucleosomes in the path of the elongating 
RNA Polymerase II. 
However, a systematic study of the in vivo occupancy of promotors and open reading 
frames in Saccharomyces cerevisiae did not detect the Elongator Complex under any conditions. 
Interestingly, further analysis indicated that a majority of the complex was cytoplasmic (20). In 
contrast, RNA immunoprecipitation experiments showed that the Elongator complex was present 
at actively transcribed genes and was cross-linked to nascent pre-mRNA of Saccharomyces 
cerevisiae genes (21). In human cells, several genes and cellular functions were affected by RNAi 
depletion of the Elongator Complex (13). These conflicting studies suggested that the main role of 
the complex in transcriptional elongation required revision.   
 
Role of Elongator Complex in cytoplasmic kinase signaling  
NF- B is a transcriptional activator that controls immune and inflammatory responses and 
is activated by cytokine-activated I B kinases (IKKs). Elp1 was initially discovered as IKAP 
(IKK-complex-associated protein), which assembles IKKs and NIK (NF- B-inducing kinase) into 
an active kinase complex. IKAP was shown to be a scaffold protein and a regulator for kinases 
involved in pro-inflammatory cytokine signaling (22). However, a subsequent study refuted these 
claims and suggested a general role in transcription and not specifically in signaling to cytokine-
related genes (23).  
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Role of Elongator Complex in exocytosis 
Rab proteins are nucleotide-dependent molecular switches that regulate vesicular 
trafficking in eukaryotic cells (24). Elp1 was shown to physically interact with Sec2p, a Rab 
GTPase involved in transport of secretory vesicles to the bud-tip in Saccharomyces cerevisiae. 
This interaction was shown to be necessary for Elp1 function and localization of Sec2p. Thus, it 
was proposed that the Elongator complex is necessary for the regulation of exocytosis by 
associating with Sec2p (12).  
 
Role of the Elongator complex in tRNA modification 
tRNAs have a large number of diverse post-translational modifications and these require 
one or more enzymatic steps. A survey of 561 sequences tRNAs from several organisms shows 
that modifications are found on 11.9% of residues, with a median of 8 modifications per tRNA 
species (25,26). Of the 50 modifications found in eukaryotic tRNAs, 25 different modifications 
were found in cytoplasmic tRNAs of Saccharomyces cerevisiae (27). Also, in Saccharomyces 
cerevisiae, these modifications occur at 36 different positions, with an average of 12.6 
modifications per species (28) (Fig 1.4). Of the 76 nucleotides in tRNA, most modifications are 
found in the anticodon loop, and especially at position 34 (wobble position in tRNA) (Fig 1.5). To 
read 61 codons (not including the stop codons) in mRNA, the first base of the anticodon (position 
34) usually recognizes different bases at the third base of the codon in mRNA due to the limited 
number of tRNAs that encode the 20 amino acids. Many functions of these modifications have 
been studied: (i) modifications around the anticodon loop affect translation or growth (29) (ii) 
modifications in the main body affect tRNA folding or stability (30) (iii) some modifications affect 
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tRNA identity (31). The nucleotide at position 34 is usually extensively modified, which ensures 
high efficiency and fidelity of protein translation (32-36). 
Kluyveromyces lactis secrets a toxin named zymocin that irreversibly inhibits cellular 
growth of Saccharomyces cerevisiae and, after 20 years, the Elongator Complex was found to be 
the intracellular toxin target. Also, growth inhibition did not occur in cells lacking elp1-6 and killer 
toxin insensitive (Kti) genes, namely kti11, kti12 and kti13 (37). Mutants of Kti11-13 have similar 
pleiotropic phenotypes to those of ELP1-6 mutants (38). Furthermore, Kti11 and Kti13 were 
shown to physically interact with the Elongator complex (39,40). A significant discovery by 
Byström and coworkers showed that nine proteins, Elp1-6 and Kti11-13, are required for the 
formation of 5-methoxycarbonylmethyl (mcm5) and 5-carbamoylmethyl (ncm5) groups on the 
uridine at the wobble position in tRNAs (Fig 1.3). The lack of these modifications caused defects 
in decoding, potentially causing the pleiotropic phenotypes exhibited by elp and kti mutants (41).  
Zymocin consists of three subunits named α, β and γ. Of the three subunits, γ-toxin confers 
cytotoxicity (42). Three tRNA species were shown to be the target of the γ-toxin: 
tRNAGlumcm5s2UUC, tRNA
Lys
mcm5s2UUU, and tRNA
Gln
mcm5s2UUG. The tRNAs are cleaved at the 3' side 
of the modified wobble uridine 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U) resulting in 
growth inhibition. tRNA lacking a part of or the entire mcm5 group is inefficiently cleaved by 
gamma-toxin, explaining the gamma-toxin resistance of the modification-deficient elp1-elp6 and 
kti11-kti13 mutants. Interestingly, the γ-toxin is the first eukaryotic toxin shown to target tRNA 
(43). Another significant study demonstrated that overexpression of tRNALysUUU, tRNA
Gln
UUG and 
tRNAGluUUC suppressed all defects associated with the Elongator deletions including histone 
acetylation levels, exocytosis, telomeric gene silencing and DNA repair (16,44). This was further 
supported by a study of the Ncs2 protein which is required for the formation of the 2-thio group at 
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the wobble position in tRNAs. The ncs2 mutant, which is unable to form the s2, shows identical 
(but weaker) phenotypes to the Elongator deletion (45-47). It has been suggested that the 
modifications stabilize stacking interactions and promote a canonical loop structure favorable for 
base pairing with the mRNA (48,49).This data suggests that the defects are indirect and caused by 
the inability to modify these tRNA species (and protein translation, as a result), which leads to 
multiple downstream effects.  
Of the 42 cytoplasmic tRNAs in Saccharomyces cerevisiae, 13 have a U at the wobble 
position (U34) (50). Of these, 11 have either the ncm5U or mcm5U modification. tRNALeuUAG has 
an unmodified U and  tRNAIleΨAΨ has a pseudouridine at U34 (51-58). Since approximately 25% 
of cytoplasmic tRNAs are modified, the lack of this modification can cause severe effects.   
 
Defects in cellular functions associated with the Elongator complex 
Defects in the Elongator complex have been shown to affect U34 modifications in Mus 
musculus, Caenorhabditis elegans, Arabidopsis thaliana, Drosophila melanogaster (59) and 
human (60-63). In Saccharomyces cerevisiae, mutations in the Elongator complex are associated 
with hypersensitivity to stress (18). In Arabidopsis thaliana, mutations are associated with cell 
proliferation and growth defects (64). In Caenorhabditis elegans, mutations cause neurological 
and developmental defects (65). In Drosophila melanogaster, mutations have been associated with 
several processes including larval- and neuro-development (66). In Mus musculus, mutations are 
impair zygotic paternal genome demethylation and are embryonic lethal (15,67). Mutations in the 
Elongator complex are also associated with human diseases like Familial Dysautonomia, which is 
characterized by defects in the development and survival of neurons of the autonomic and sensory 
systems (68,69). Variants in Elp4 alleles have been associated with rolandic epilepsy, which is a 
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neurodevelopmental disorder characterized by seizures and developmental defects (70). Allelic 
variants of Elp3 have also been associated with amyotropic lateral sclerosis, which is characterized 
by degeneration of motor neurons resulting in muscle weakness and atrophy (14).  
Chapter 2 provides insight into the tRNA wobble uridine modification in vivo, Chapter 3 
describes the in vitro reconstitution of the Elp3-catalyzed reaction, and Chapter 4 provides insight 
into the structure of Elp3.    
 
Radical SAM enzyme: viperin  
 Following the study of Elp3, bioinformatics analysis was performed to further understand 
the number of radical SAM enzymes, their distribution among the three domains of life and the 
number found in humans. The results were displayed in a sequence similarity network (SSN) of 
the radical SAM superfamily (Fig. 1.6). The analysis revealed that the radical SAM superfamily 
consists of 125,000 unique sequences, a majority of which are found in bacteria (Fig. 1.6, blue 
nodes). Archaea also have a significant number of enzymes (Fig. 1.6, green nodes) and several 
families (denoted by the clusters in Fig. 1.6) are unique to archaea. Eukarya have the least number 
of radical SAM enzymes distributed in ~20 clusters (Fig. 1.6, magenta nodes).  
 Humans have eight canonical radical SAM enzymes (Fig. 1.3, boxed clusters), equally 
distributed between the mitochondria and cytoplasm. Although no human enzymes have been 
biochemically and structurally characterized, their biological functions can be inferred from 
studies of their homologs in bacteria and archaea.  RSAD1, MOCS1 and LIAS are likely involved 
in cofactor biosynthesis and Elp3, Cdk5rap1, CDKAL1 and TYW1 may be involved in tRNA 
modification (71-79). The fact that viperin is the only human enzyme that is involved in a different 
function – viral replication – prompted us to further investigate the mechanism of action.   
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Viral infection, in mammalian cells, results in the induction of several viral recognition 
pathways which results in the activation of innate defenses to limit viral replication, one of which 
is the induction of interferon (IFN) (80). The three types of IFNs are: type I IFNs (IFN-α, IFN-β), 
type II IFN (IFN-γ) and type III IFNs (IFN-λ1, IFN-λ2, IFN-λ3). The IFN response triggers the 
induction of a broad array of interferon-stimulated genes (ISGs), which act to limit viral 
replication. Some IFN-inducible proteins like protein kinase R, GTPase Mx1 and ribonuclease L 
have been well characterized as antiviral effectors (81-83); however, the role of most ISGs remains 
elusive. Viperin (virus inhibitory protein, endoplasmic reticulum-associated, interferon-inducible) 
is an IFN-inducible protein which has shown to have direct antiviral activity.  
Viperin was identified while analyzing the response of human macrophages to the IFN-γ 
response (84). It was initially discovered as cig5 (cytomegalovirus-inducible gene 5) while 
analyzing differential display analysis of primary fibroblasts infected with human cytomegalovirus 
(HCMV) (85). Viperin has also been shown to be induced by IFN-α, IFN-β, double-stranded DNA, 
double-stranded RNA, lipopolysaccharide and infection with viruses, with the majority of them 
being ssRNA (86-95). However, the molecular mechanism by which viperin limits viral replication 
is unknown.  
Human viperin is composed of 361 amino acids and is approximately 42kDa. It consists of 
a variable N-terminal domain, a conserved central domain containing the CX3CX2C radical SAM 
motif and a highly conserved C-terminal domain (Fig 5.1). The N-terminal domain contains an 
amphipathic α-helix. This has been known to allow viperin to associate with the cytosolic phase 
of the endoplasmic reticulum (ER) and lipid droplets (96,97). Viperin has been shown to bind 
[4Fe-4S] and catalyze the reductive cleavage of SAM (98). Furthermore, the [4Fe-4S] binding 
motif is essential for its antiviral activities in hepatitis C virus (HCV) and HCMV (91,99). The 
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aromatic amino acid at the C terminus of viperin is also required for its antiviral activity against 
HCV (99). Therefore, this residue may be involved in protein-protein interactions and/or substrate 
recognition (100).  
Viperin expression was shown to inhibit influenza A and HIV-1 by blocking viral 
replication. HeLa cells expressing murine or human viperin has been shown to inhibit viral 
budding from the plasma membrane by disrupting lipid rafts and increasing membrane fluidity 
(90,101). Lipid rafts play an important role in the replication cycle of many viruses and the 
envelopes of influenza virus and HIV are enriched in raft lipids (102,103). A study that has been 
integral to this investigation demonstrated that viperin could bind and inhibit farnesyl diphosphate 
synthase (FPPS), an enzyme essential for isoprenoid biosynthesis, including cholesterol. Also, the 
inhibition of virus production and normal membrane fluidity was restored by overexpressing 
FPPS. This suggests that targeting the release stage of the viral life cycle may affect the replication 
of several enveloped viruses. This is the first ISG that has been shown to inhibit the final stage of 
viral replication (104). Chapters 4 discusses the in vitro reconstitution of the viperin-catalyzed 
reaction and Chapter 5 discusses structural studies of viperin.  
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1.2. Figures 
 
 
 
Fig 1.1. Components and chemistry required for generating 5’-dA• by radical SAM enzymes. In 
addition to the protein enzyme, a [4Fe-4S] (red/orange) is incorporated into the enzyme via 
coordination with side chains of three conserved cysteine residues (green). Additional components 
required for the radical reaction are cofactor SAM (blue) and an electron from an external source. 
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Fig 1.2. Composition and conservation of the Elongator complex in eukaryotic organisms.  A. 
Schematic view of six subunits of the human Elongator complex.  Only the domains of the catalytic 
subunit, Elp3, are defined and highlighted in color.  An arrow denotes the location of CX9CX2C 
motif that binds an [4Fe-4S].  KR, lysine and arginine rich domain; HAT, histone acetyltransferase 
domain.  B. Cartoon depiction of core complex Elp1-3 and sub-complex Elp4-6, which form the 
entire Elongator complex.  Recent structural studies show formation of a heterohexamer of the 
yeast Elp4-6 sub-complex instead of the heterotrimer depicted here.  C. Varying conservation of 
Elp subunits from human to yeast.  Each human Elp was compared to its counterpart in yeast and 
the percentage of the sequence identities were plotted on a vertical black bar.  NA, not aligned. 
 
                        
 
Fig 1.3. Summary of modifications at C5 of U34 in tRNAs from three model organisms.  A. 
Distribution of modifications in U34-containing tRNAs.  Only the modifications at C5 of U34 are 
highlighted in color.  m: 2’-O-methylation; s2: 2-thiolation.  B. Chemical structures of three 
modifications at C5 of U34. 
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Fig 1.4. A schematic view of modifications found in cytoplasmic tRNA in Saccharomyces 
cerevisiae (28).  
 
 
 
 
                                              
Fig 1.5. Position 34 (wobble position) of tRNA base pairs with the 3rd position of the codon 
in mRNA. 
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Fig 1.6. A global view of radical SAM enzymes in three domains of life. Each node represents a 
collection of radical SAM enzymes sharing >70% sequence identities. Each edge (gray line) 
connects two nodes if the E-value measuring the two nodes is <1e-50. The clusters containing 
human enzymes are boxed and numbered. The letters after the numbers denote location of the 
enzymes (c, cytoplasm; m, mitochondria). 1c, Elp3; 2m, RSAD1; 3m, Cdk5rap1; 4c, CDKAL1; 
5m, MOCS1; 6m, LIAS; 7c, Viperin; 8c, TYW1.  
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CHAPTER 2: CHARACTERIZATION OF IN VIVO TRNA WOBBLE URIDINE 
MODIFICATION 
 
2.1. Introduction 
 
Two major and one minor tRNA modification at C5 of U34 are chemically and 
mechanistically different 
As discussed in Chapter 1, the uridine at the wobble position (U34) is extensively modified 
to ensure high efficiency and fidelity of protein translation. Uridine can undergo one of three 
modifications at C5 on the base (Fig 2.1). The type of modification depends on the organism and 
if it is a eukaryote, it depends on the location of the tRNA within the cell (cytoplasm or 
mitochondria). In almost all tRNA from bacteria and from the mitochondria of eukaryotes, tRNAs 
with an anticodon UAA, UUX and UCX are modified by the MnmE-MnmG complex, resulting in 
the addition of a carboxymethylaminomethyl (cmnm) group, or its decarboxylated derivitive 
methylaminomethyl (mnm) (105-109). In approximately 20% of bacteria (belonging to the 
Proteobacteria phylum), the remaining tRNAs have a different modification, with the addition of 
an oxyacetyl (cmo) group or its methylated derivative methyloxyacetyl (mcmo) (110,111). This 
involves a novel mechanism involving the conversion of SAM to carboxyl-SAM by CmoA (SAM 
dependent methyltransferase), followed by the transfer of a carboxymethyl (cm) group from 
carboxyl-SAM to the hydroxyl group at C5 of U34 in tRNA by CmoB (another SAM dependent 
methyltransferase) (112). The third type of modification is found in cytoplasmic tRNAs of 
eukaryotes, which have a methoxycarbonylmethyl (mcm) or carbamoylmethyl (ncm) group on 
almost all U34 containing tRNAs. Since Saccharomyces cerevisiae  Elp1-2 and Elp4-6 mutants 
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have the same pleiotropic phenotypes and lack of the U34 modification as the Elp3 mutant, it was 
suggested that the Elongator complex was responsible for the early step of this modification by 
catalyzing the addition of a carboxymethyl (cm) group at C5 of U34 (41). This was further 
supported by the identification of the methyltransferase Trm9, which catalyzes the addition of the 
last methyl group with the assistance of Trm112 (a zinc finger protein) to form mcm5U (113,114) 
(Fig. 2.2). Interestingly, the overall modification reaction (transfer of a cm group to U34) 
performed by the Elongator complex is similar to the one performed by the CmoA-CmoB complex. 
However, the chemical reactions are vastly different.   
The goal of this chapter is to describe our attempts to understand the in vivo tRNA 
modifications in yeast and two archaea.  
 
2.2. Materials and Methods 
 
Isolating total tRNAs for HPLC (shorter version of tRNA purification, less pure) 
This technique worked well for Saccharomyces cerevisiae and Escherichia coli. 1 L of 
cells (grown to 1 O.D) was re-suspended in 6 mLs Resuspension buffer (0.3 M NaOAc (pH 4.5), 
10 mM EDTA) and vortexed well. 6 mL phenol was added and vortexed 3 times for 1 minute each 
with a 1 minute interval. Solution was transferred to 15 mL conical tubes and mixture was 
centrifuged at 3,500 RPM for 15 minutes. The aqueous layer (avoiding the layer in between) was 
transferred to a new tube. 6 mL of phenol:chloroform pH 6.6 was added. Tubes were inverted 
several times and centrifuged at 3,500 RPM for 15 minutes. The aqueous layer was transferred to 
a centrifuge tube, 2.5x volumes of cold ethanol was added and solution was cooled at -20 °C 
overnight. Solution was centrifuged at 20,000 RPM for 15 minutes. The pellet was air-dried in the 
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hood for 6-8 hours. Pellet was re-suspended in DEPC H2O or TE pH 7.0. Equal volume of 4 M 
LiCl in 0.2 M NaOAc pH 4.5 was added, mixed well and incubated on ice for 10 minutes. Sample 
was centrifuged at 13,000 RPM for 15 minutes. The supernatant was transferred to a new tube and 
2.5x volumes of cold 100% ethanol was added and sample was incubated overnight at -20°C. The 
tRNA was precipitated by centrifuging at 20,000 RPM for 20 minutes. The pellet was air-dried 
and re-suspended in DEPC H20, TE pH 7.0 or Hybridization buffer (for isolating individual tRNAs 
using biotinylated DNA). Note: When purifying directly from cells, unbuffered phenol was used 
first and buffered phenol:chloroform was used second; else, separation did not occur).  
 
Isolating total tRNAs for UPLC (longer version of tRNA purification, more pure) 
Total tRNAs were isolated using the single-step method of RNA isolation by acid 
guanidinium thiocyanate-phenol-chloroform extraction (115, 116) with the changes noted below. 
Specifically, 1 g of cells (Saccharomyces cerevisiae, Methanococcus maripaludis, Sulfolobus 
acidocaldarius and Escherichia coli) was re-suspended in 5 mL extraction buffer (4 M guanidine 
isothiocyanate, 0.5% (w:v) Sodium N-laurylsarcosine, 25 mM sodium citrate pH 7, 110 mM 2-
mercaptoethanol. Note: “solution D” was made first by adding the first 3 chemicals. 2-
betamercaptoethanol was added right before use to make a “working solution”) by vortexing in a 
50 mL conical tube (Note: separation was better in a 15 mL conical tube; however, 50 mL conical 
tube was necessary in this case). 500 uL of 2 M Sodium acetate (pH 4.1) (Note: acetic acid was 
used to buffer) and 5 mLs of unbuffered phenol was added. Tubes were rotated overnight (~12 
hours) at 4 °C. 1 mL of chloroform:isoamyl alcohol (49:1) was added (Note: This was made right 
before use). Solution was mixed and tubes were incubated on ice for 15 minutes. Tubes were 
centrifuged at 3,500 RPM for 20 minutes (Note: in some cases, like Escherichia coli, a clear 
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separation was seen; however, this was not the case for all organisms). To create a clear separation 
of layers, an additional 6mL chloroform:isoamyl alcohol (49:1) was added to all tubes and mixed. 
Solution was separated into 15 mL conical tubes to see the separation better. All tubes were placed 
on ice for 15 minutes. Tubes were centrifuged at 3,500 RPM for 20 minutes (Note: At this point, 
2 layers were clearly visible). Next, the top layer was carefully removed (avoiding the layer in 
between) and 2 volumes of cold 100% ethanol was added and stored in -20 °C overnight (minimum 
3 hours) in a clean centrifuge tube. Sample was centrifuged at 20,000 RPM for 20 minutes. The 
pellet was completely dried at room temperature under the hood for 6-8 hours. The pellet was re-
suspended in 1 mL Binding buffer (100 mM NaCl and 10 mM Tris-Hcl pH 7.0) (Note: Buffer was 
added and allowed to re-suspend for 0.5-1 hr. In some cases, it was required to break apart the 
pellet for some organisms.) The re-suspended tRNA was transferred to 1.5 mL microcentrifuge 
tube and spun at 12,000 RPM for 2 minutes to remove any particles. The sample was diluted to 5 
mL with Binding buffer and filtered using a 0.45 uM filter. 
Next, the tRNA was manually purified using a 5 mL DEAE column (GE Healthcare). The 
column and all buffers were chilled at 4 °C before use. The DEAE column was washed with 5 mL 
of Binding buffer. 5 mL of sample was injected. Column was washed with 10 mLs of Binding 
buffer (250 mM NaCl and 10 mM Tris-Hcl pH 7.0). Next, column was washed with 15 mL of 
Elution buffer (1 M NaCl and 10 mM Tris-Hcl pH 7.0). Next, ethanol precipitation was performed 
by adding 2.5 volumes of ethanol and cooling in -20 °C overnight. Next, 10 mL centrifuge tubes 
were used to spin down sample as the pellet was very small (spun at 10,000 RPM for 20 mins as 
these tubes break above 10,000 RPM). Pellet was dried for 6-8 hours in the hood. The pellet was 
re-suspended in 80% ethanol and allowed to sit at room temperature for 10 minutes. Samples were 
centrifuged again at 10,000 RPM for 20 minutes and dried under the hood. Samples were re-
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suspended in DEPC treated H20. tRNA was analyzed by running on a 2% agarose gel (in vitro 
transcribed tRNA was used as a control).  
 
Designing 5’ Biotin-labeled DNA probes for isolating specific tRNA from total tRNA 
Probes were designed complementary to the 3’ end of the tRNA (ignoring the CCA end 
since this is same for all tRNAs. The probe was approximately 31 nucleotides long ending in a C 
or G if possible. Probes were ordered in 250 nmole scale with the addition of Biotin at the 5’ end 
from IDT. For example, the following probe was ordered to specifically hybridize with 
MmatRNAArgUCU: 
Methanococcus_maripaludis_S2_ArgTCT 
5’GGGCCCGTGGCCTAGTCTGGATACGGCACCGGCCTTCTAAGCCGGGGATCGGGGG
TTCGAATCCCTCCGGGTCCGCCA3’ 
Biotin-Mma-tRNA-ArgUCU 
5’GGC GGA CCC GGA GGG ATT CGA ACC CCC GAT3’ 
 
Isolating specific tRNAs using biotinylated single-stranded DNA from total tRNA 
Streptavidin Sepharose High Performance beads (17-5113-01, GE Healthcare) were gently 
re-suspended in the bottle. 0.5 mL beads were loaded onto 0.22 uM centrifugal filter units 
(UFC30GV00, Millipore). Next, the filter units were centrifuged at 1000 RPM for 2 minutes to 
remove ethanol solution. Next, the beads were washed with PBS buffer and spun at 1000 RPM for 
2 minutes. DNA probes (described above) were dissolved in 400 uL TE pH 8. 100 uL of DNA 
probe was mixed with 200 uL PBS buffer. OD was measured by mixing 0.5 uL solution with 100 
uL water (same ratio was used for all measurements).  Mixture was loaded into centrifuge tube 
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and mixed gently. Tubes were incubated in a 25 °C water bath for 15 minutes. Next, they were 
spun at 1000 RPM for 2 minutes. OD of flow-through was measured. Beads were washed with 
PBS buffer and spun at 1000 RPM for 2 minutes. Next, the beads were incubated with total tRNA 
which was re-suspended in 400 uL (or more if necessary) 1x Hybridization buffer (40 mM Tris-
Hcl pH 7.5, 1.8 M TmAc, 200 mM EDTA in DEPC H20). Note: All particles were removed in the 
total tRNA solution by centrifuging at 12,000 RPM for 1 minute and filtering with filter units. 
Total tRNAs were incubated with beads at 65 °C for 10 minutes (bead mixture was re-suspended 
after 5 minutes because the beads settle). The sample was centrifuged at 1000 RPM for 2 minutes 
and the flow-through was collected and OD was measured. Centrifuge tube was washed with 1x 
Hybridization buffer twice (the flow-through, Wash 1 and Wash 2, were collected and OD was 
recorded). Next, the tRNAs bound to the beads were eluted using Elution Buffer (20 mM Tris-Hcl 
pH 7.5 in DEPC H20). 400 uL of Elution buffer was added and bead mixture was incubated at 65 
°C for 10 minutes (sample was mixed after 5 minutes). Beads were spun at 2000 RPM for 2 
minutes to collect Elution 1. Another 400 uL of Eluting Buffer was added and beads were 
incubated for 10 minutes at 70 °C. Tubes were spun at 2000 RPM for 2 minutes to collect Elution 
2. Another 400 uL of Eluting Buffer was added and the tubes were incubated for 10 minutes at 75 
°C. Tubes were spun at 2000 RPM for 2 minutes to collect Elution 3. OD was measured for Elution 
1, 2 and 3. Ethanol precipitate was performed for all samples (FT, W1, W2, E1, E2, E3) by adding 
40 uL 3 M NaOAc (pH 5.2) and 2.5x volumes (1 mL) cold ethanol. Samples were cooled overnight 
at -20 °C or placed on dry ice for 20 minutes. Samples were centrifuged at 12,000 RPM for 20 
minutes. The pellet was air dried in the hood for 3-5 hours or until fully dry. Pellet was re-
suspended in 20 uL TE pH 7 or DEPC H20. Equal volume of DPAGE gel loading solution was 
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added and sample was heated at 95 °C for 3 minutes and cooled on ice for 10 minutes. tRNAs 
were purified using a 15% gel and the crush and soak technique. 
 
Purifying RNA from gel using Crush and Soak technique 
Gel was peeled and placed in between two sheets of plastic wrap. Gel was visualized using 
UV and TLC plates and bands to be purified were marked. Bands were cut using a razor, placed 
into a tube and crushed using a rounded glass rod. Elution buffer (0.5 M ammonium acetate, 1 mM 
EDTA in filtered DEPC H20) (~3mL to purify a 4 mL reaction of in vitro transcribed tRNA or ~ 
800 uL for a specific band) was added and tubes were rotated for 30 minutes. Tubes were spun to 
separate gel pieces from solution (for large volume, tubes were spun at 3,500 RPM for 10 minutes; 
for small volume, tubes were spun at 13,000 RPM for 2 minutes). To ethanol precipitate solutions, 
1/10th the volume of 3 M sodium acetate (pH 5.2) and 2.5 x cold ethanol was added. Tubes were 
cooled at -20 °C overnight or on dry ice for 20 minutes. Tubes were spun at 12,000 RPM for 20 
minutes. Pellet was dried in the hood for several hours until the pellet was completely dry. It was 
re-suspend in DEPC H20 or TE pH 7. 
 
Designing templates for in vitro transcription of tRNAs 
Two templates were designed for each tRNA to be transcribed. Template 2 was 
complementary to the entire tRNA to be transcribed with the T7 promoter sequence at the 3’ end. 
Template 1 was a shorter template with the T7 promoter sequence at the 5’ end and the first two 
bases to be transcribed. Template 1 was ordered in 100 nmole scale and Template 2 was ordered 
in 250 nmole scale from IDT (Table 2.1).  
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In vitro transcription for tRNAs 
Both templates were dissolved in 100 uL TE pH 8 and were gel purified and ethanol 
precipitated. Equal amounts of both templates were mixed and heated for 95 °C for 3 minutes. The 
heating block was removed and placed outside to cool down to room temperature. Note: For 
example, 30 uL of 20 uM Primer 1 was added to 30 uL of 20 uM Primer 2 to get a final of 60 uL 
of 10 uM annealed template. The annealed primer was then used to test for optimal template 
concentration (For example, 1.5, 0.75, 0.375, 0.18, 0.09 uM final concentration of template in 
reaction solution) in 40 uL scale. The in vitro transcription reaction was set up in 1x Reaction 
buffer (0.4 M Tris-Hcl pH 7.9, 0.06 M MgCl2, 0.1 M dTT, 0.02 M Spermidine), 1.25 mM of each 
rNTP (pre-made 100 mM stock), 50 mM dithiothreitol, 0.1 mg/ml T7 polymerase (2 mg/ml stock 
in 40% glycerol) and appropriate template concentration. For this study, all in vitro transcription 
of tRNA was done using 0.09 uM final template concentration in an 8 mL reaction volume. The 
reaction was incubated at 37 °C overnight. The next morning, the sample was centrifuged to 
remove precipitant. Equal volume of DPAGE loading dye was added and it was incubated at 95 
°C for 3 minutes followed by cooling on ice for 10 minutes. The sample was then purified on a 
15% gel and tRNA was extracted using the Crush-and-soak technique. The tRNA was precipitated 
using ethanol precipitation. The pellet was dried and tRNA was re-suspended in TE pH 7 or DEPC 
H20.  
 
Purification of T7 polymerase 
Plasmid containing T7 polymerase (ampicillin resistant) was transformed into BL-21 and 
expressed at 18 °C overnight. Protein was first purified using the AKTA FPLC using a Nickel 
column (Ni A: Tris-HCl pH 8.0, 100 mM NaCl, Ni B: Tris-HCl pH 8.0, 100 mM NaCl, 500 mM 
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imidazole). Fractions were pooled and diluted using DEAE A buffer (20 mM Tris-HCl pH 8.0, 10 
mM NaCl, 2% glycerol). Next, the protein was purified using a Heparin column using DEAE A 
and DEAE B buffer (20 mM Tris-HCl pH 8.0, 1 M NaCl, 2% glycerol). Protein was concentrated 
and stored in 40% glycerol in -80 °C (2 mg/ml final concentration). 
 
Analysis on HPLC and LC-MS 
To analyze the modified nucleoside, the tRNA product was first digested by P1 nuclease 
in a P1 buffer (10 mM sodium acetate (pH 5.1), 0.5 mM ZnCl2). This was followed by digestion 
with Calf Alkaline Phosphatase (CAP) in a CAP buffer (20 mM Tris-HCl (pH 8.5), 20 mM NaCl, 
1 mM MgCl2). RP-HPLC analysis was carried out with a Waters 1525 HPLC system on a C18(2) 
Luna column (250 mm × 2 mm, Phenomenex) with a flow rate of 0.3 mL/min. For analysis of the 
tRNA digest, solvent A was 5 mM ammonium acetate (pH 5.3), solvent B was 40% acetonitrile in 
water and the following gradient was used: 0.0 min, 0% B; 0.5 min, 0% B; 15 min, 20% B; 25 
min, 22% B; 35 min, 30% B; 43 min, 50% B; 48 min, 50% B; 53 min, 0% B; 60 min, 0% B. For 
analysis of SAM, acetyl-CoA, and 5′-dA, solvent A was 50 mM sodium phosphate (pH 6.5), 
solvent B was 40% acetonitrile in water, and the following gradient was used: 0.0 min, 0% B; 5 
min, 20% B; 15 min, 28% B; 19 min, 50% B; 22 min, 50% B; 26 min, 0% B; 30 min, 0% B. 
ESI-LC/MS experiments were carried out at the School of Chemical Sciences Mass 
Spectrometry Laboratory of the University of Illinois with a Waters 2795 HPLC system and a 
Waters Q-TOF Ultima API Mass Spectrometer. The absorption was monitored by UV (220–310 
nm), and the mass was monitored in positive mode. The same column and gradients described 
above were used for ESI-LC/MS. The solvents for ESI-LC/MS were 5 mM ammonium acetate (pH 
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5.3) (solvent A) and 40% acetonitrile in water (solvent B). The synthetic cm5U used for 
comparison via RP-HPLC and ESI-LC/MS was a generous gift from Y. Fu and C. He (121). 
 
2.3. Results and Discussion 
 
Elp3 is the only subunit in archaea, some bacteria and two viruses 
A bioinformatics analysis was performed to explore the presence of Elp3 in the organisms 
that have been sequenced to date. A BLASTp search was performed using human Elp3 (HsaElp3) 
as the seed to retrieve similar amino acid sequences. The sequences were then subject to all-versus-
all BLASTp, and the results were displayed as a sequence similarity network on Cytoscape (Fig. 
2.3). As expected, the results indicated that Elp3 was found in many eukaryotes (407, magenta). 
Apart from eukaryotes, Elp3 was also found in almost all archaea (220, green), a few bacteria (47, 
blue) and two viruses (cyan). 
 The sequence similarity network also revealed that Elp3 can be divided into three clusters. 
The majority of Elp3 belongs to Cluster 1, including a majority of eukaryotic Elp3, all archaeal 
Elp3 and bacteria of the Chloroflexi phylum. Cluster 2 contains Elp3 from nine parasitic species 
belonging to the Plasmodium phylum. Cluster 3 contains Elp3 from bacteria belonging to the 
Actinobacteria phylum.  
 Since all six subunits of the complex are present in the eukaryotes studied to date 
(9,63,60,66,117), it could be assumed that the other higher eukaryotes (in the lower part of Cluster 
1) also have all six subunits of the Elongator complex. Interestingly, all the archaea and bacteria 
on this map do not have Elp1-2 and Elp4-6. To explore this further, a BLASTp search was 
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performed for the lower eukaryotes (upper part of Cluster 1 and Cluster 3). The results showed 
that the lower eukaryotes have only Elp3, and not the other 5 subunits.  
  
All archaea and bacteria with Elp3 do not have genes encoding MnmE-MnmG 
An in vitro reconstitution experiment clearly demonstrated that the MnmE-MnmG 
complex is responsible for the cmnm5U34 modification in bacteria (106) (Fig. 2.4). The presence 
or absence of the mnmE and mnmG genes can indicate if an organism contains cmnm5U34 or 
mnm5U34 in its tRNAs. The results of the BLASTp search showed that all the archaea and the 
bacteria with Elp3 do not have mnmE and mnmG genes. Thus, it is likely that the archaea and 
bacteria with Elp3 do not have the cmnm5U34 or mnm5U34 modification in their tRNAs.  
If the U34 containing tRNAs in these archaea and bacteria (with Elp3) are modified, then 
they are likely to be the same as the modification found in the cytoplasmic tRNAs of eukaryotes. 
Furthermore, Elp3 alone is likely responsible for catalyzing the early stages of this modification 
because these archaea and bacteria (with Elp3) do not have Elp1-2 and Elp4-6.  
 
LS-MS identified two potentially new modified nucleosides in archaeal tRNAs 
To establish a system to analyze tRNAs, in vitro transcribed MintRNAArg was digested and 
analyzed via HPLC. As expected, we see four peaks corresponding to C, U, G and A. RNA stem-
loops containing cm5U and mcm5U were also digested and analyzed via HPLC. Two small peaks 
were detected (Fig. 2.5).  
 To study the in vivo modification at C5 of U34, total tRNAs were isolated from 
Saccharomyces cerevisiae and Methanococcus maripaludis (Euryarchaeota). Next, MmatRNAArg 
and ScetRNAArg were specifically isolated via affinity purification using biotinylated single-
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stranded DNA specific for these sequences. The isolated tRNA was then enzymatically digested 
and the resulting nucleosides were analyzed by HPLC and LC-MS (Fig. 2.6) 
 As expected, ScetRNAArg contains mcm5U, which was confirmed by LC-MS (Fig. 2.7A) 
and by co-elution and comparison with the synthetic compound. In MmatRNAArg, cm5U (the 
product of the Elp3 catalyzed reaction (Chapter 3) was not found. Furthermore, neither mcm5U 
nor ncm5U (the U34 modifications found in cytoplasmic tRNAs of eukaryotes) were found (Fig. 
2.7C). However, a new compound corresponding to a molecular weight of 549 Da was detected 
using LC-MS (Fig. 2.7D). This compound does not match any of the 109 known modified 
nucleosides in the RNA Modification Database.  
 To further investigate this result, we isolated total tRNAs from Saccharomyces cerevisiae 
and two archaea using a more sensitive purification protocol. One archaea belongs to 
Euryarchaeota (Methanococcus maripaludis) and the other belongs to Crenarchaeota (Sulfolobus 
acidocaldarius). The total tRNA was gel purified, enzymatically digested and the resulting 
nucleosides were analyzed by UPLC and LC-MS. As expected, Saccharomyces cerevisiae has 
mcm5U and ncm5U, which is found in the cytoplasmic tRNAs of eukaryotes. This was confirmed 
by LC-MS and by comparison to the synthetic compound. Similar to the previous study, cm5U, 
ncm5U and mcm5U were not detected in either archaea and the compound corresponding to the 
molecular weight of 549 Da was detected again (Fig. 2.8A). We also detected another new 
compound corresponding to 454 Da (Fig. 2.8B). It may be possible that tRNA U34 in archaea have 
a common first step with the addition of a cm5U group and may have a second step which is 
different from the one found in eukaryotes. 
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2.4. Tables and Figures 
 
 
Fig 2.1. Mechanism for CmoA and CmoB catalyzed formation of cmo5U at U34 of bacterial 
tRNAs.  
 
 
 28 
 
                                        
Fig 2.2. Model for formation of mcm5 side chain at wobble uridines. The Elongator complex 
(Elp1-Elp6) and its potential regulators are required for the formation of cm5U. A methyl group is 
added to cm5U by the Trm9p/Trm112p complex in tRNA species that in their mature form should 
have a mcm5 side chain. The cm5U in other tRNA species are converted to ncm5U by an unknown 
enzyme. For tRNAs that should contain a s2 group, presence of a mcm
5 or ncm5 side chain is a 
prerequisite for efficient thiolation (118). 
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Fig 2.3. Visualization of the presence of Elp3 in different domains of organisms. The results of a 
pairwise BLASTp of Elp3 sequences were displayed as a sequence similarity network in Organic 
layout using Cytoscape. Each node (colored circle) represents an individual Elp3. An edge (gray 
line) connects two nodes if the E-value measuring the sequence similarities is smaller than the 
cutoff value, which was set at 1e-75. The nodes marked by an asterisk and a number sign represent 
human and yeast Elp3, respectively, and the note marked by a plus sign is MinElp3. 
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Fig 2.4. The proposed chemical mechanism for the MnmE-GidA (MnmG) catalyzed reactions. 
Step 1: A general acid of MnmE•GidA converts the methylene-THF into a reactive iminium ion. 
Step 2: This allows the addition of the amine or carboxymethylamine group to the methylene group 
at N5 of THF. Step 3: FAD-bound GidA (MnmG) performs a dehydrogenation reaction. This 
facilitates the nucleophilic attack by the C5 atom of U34, which has been activated through the 
attack at the C6 position of U34 by a general acid of the MnmE-GidA complex. Step 7: 
FADH2 serves as the reducing agent of the Schiff’s base. This step is followed by the liberation of 
the MnmE-GidA (MnmG) complex and production of cmnm5U and nm5U (106). 
                   
Fig 2.5. HPLC analyses of digested in vitro transcribed MintRNAArg, cm5U containing stem-loop, 
mcm5U containing stem-loop. 
 31 
 
                           
Fig 2.6. Isolation of MmatRNAArg and ScetRNAArg from total tRNAs from whole cells using 
affinity purification. 
 
            
 
Fig. 2.7. Identification of a potentially new modified nucleoside in archaea by LC-MS. A, C. 
HPLC analyses of the digests of ScetRNAArg and MmaRNAArg, respectively. The spectra were 
truncated according to the shortest peak of C, U, G, and A (usually U).  Only the modified 
nucleotides of interest are labeled for clarity.  B. MS of mcm5U from ScetRNAArg.  D. MS of a 
potentially new modified nucleoside in MmatRNAArg. 
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Fig. 2.8. Identification of two potentially new modified nucleosides via UPLC (labeled A and B 
on the top). LC-MS of compounds labeled A and B (bottom). 
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Table 2.1. 
tRNA Template 1 Template 2 
MintRNAArgUCU- 
full length 
5’CGCCGTAATAC
GACTCACTATAGG
3’ 
 
5’TGGCGGACCCGGGGGGATTTGAAC
CCCCGACCCCCGGCTTAGAAGGCCGG
TGCCCTATCCAGGCTAGGCTACGGGT
CCTATAGTGAGTCGTATTACGGCG3’ 
MintRNAGluUUC- 
full length 
 
5’CGCCGTAATAC
GACTCACTATAGC
3’ 
 
5’TGGTGCTCCGGCCGGGATTTGAACC
CGGGTCGCGGGCTCGAAAGGCCCGC
ATGATTGGCCGGACTACACCACCGGA
GCTATAGTGAGTCGTATTACGGCG3’ 
MintRNAArgUCU- 
∆1-4 (to create a 
flat top) 
5’CGCCGTAATAC
GACTCACTATAGG
3’ 
 
5’GGACCCGGGGGGATTTGAACCCCC
GACCCCCGGCTTAGAAGGCCGGTGCC
CTATCCAGGCTAGGCTACGGGTCCTA
TAGTGAGTCGTATTACGGCG3’ 
MintRNAGluUUC- 
∆1-4 (to create a 
flat top) 
 
5’CGCCGTAATAC
GACTCACTATAGC
3’ 
 
5’GCTCCGGCCGGGATTTGAACCCGG
GTCGCGGGCTCGAAAGGCCCGCATG
ATTGGCCGGACTACACCACCGGAGCT
ATAGTGAGTCGTATTACGGCG3’ 
MintRNAArgUCU – 
U34C 
5’CGCCGTAATAC
GACTCACTATAGG
3’ 
 
5’TGGCGGACCCGGGGGGATTTGAAC
CCCCGACCCCCGGCTTAGGAGGCCGG
TGCCCTATCCAGGCTAGGCTACGGGT
CCTATAGTGAGTCGTATTACGGCG3’ 
MintRNAArgUCU- 
∆D (Join G10 and 
C25) 
5’CGCCGTAATAC
GACTCACTATAGG
3’ 
5’TGGCGGACCCGGGGGGATTTGAAC
CCCCGACCCCCGGCTTAGAAGGCCGG
TGCTACGGGTCCTATAGTGAGTCGTA
TTACGGCG3’ 
MintRNAArgUCU - 
∆T (Join C66 and 
G49) 
5’CGCCGTAATAC
GACTCACTATAGG
3’ 
5’TGGCGGACCCGGCGACCCCCGGCT
TAGAAGGCCGGTGCCCTATCCAGGCT
AGGCTACGGGTCCTATAGTGAGTCGT
ATTACGGCG3’ 
MintRNAArgUCU - 
∆D∆T  
5’CGCCGTAATAC
GACTCACTATAGG
3’ 
5’TGGCGGACCCGGCGACCCCCGGCT
TAGAAGGCCGGTGCTACGGGTCCTAT
AGTGAGTCGTATTACGGCG3’ 
MintRNAArgUCU - 
∆D∆T2-39nt (did 
not transcribe) 
5’CGCCGTAATAC
GACTCACTATAAC
3’ 
5’ACCCGGCGACCCCCGGCTTAGAAG
GCCGGTGCTACGGGTTATAGTGAGTC
GTATTACGGCG3’ 
MintRNAArgUCU - 
∆D∆T3-31nt (low 
transcription) 
5’CGCCGTAATAC
GACTCACTATAGT
3’ 
5’GGCGACCCCCGGCTTAGAAGGCCG
GTGCTACTATAGTGAGTCGTATTACG
GCG3’ 
MintRNAThrUGU 
(low 
transcription) 
(mutated parts in 
blue to break up 
row of G’s) 
5’CGCCGTAATAC
GACTCACTATAGC
3’ 
 
5’TGGAGCCCCGGGTGGGATTTGAAC
CCACGACCACCTGATTACAAGTCAGG
CGCTCTACCAGGCTGAGCCACCGAGG
CTATAGTGAGTCGTATTACGGCG3’ 
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MintRNALysUUU  5’CGCCGTAATAC
GACTCACTATAGG
3’ 
 
5’TGGCGGGCCCGAGGGGATTTGAAC
CCCCGACCACCTGGTTAAAAGCCAGG
CGCTCTGCCAGGCTGAGCTACGGGCC
CTATAGTGAGTCGTATTACGGCG3’ 
 
Table 2.1. Templates for in vitro transcription used in this study. Yellow: T7 promoter.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.1.  (cont.) 
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CHAPTER 3: ARCHAEAL ELP3 CATALYZES TRNA WOBBLE URIDINE 
MODIFICATION AT C5 VIA A RADICAL MECHANISM 
 
3.1. Introduction 
 
The eukaryotic Elongator complex is a large protein complex consisting of six subunits, 
Elp1-Elp6 (Elongator proteins). Of the six subunits, Elp3 is generally regarded as the catalytic 
subunit with two putative enzymatic domains: a radical S-adenosylmethionine (SAM) domain near 
the N-terminus and a histone acetyltransferase (HAT) domain near the C-terminus (Fig. 3.1). 
Despite the importance of Elp3, genetic studies in six eukaryotes have demonstrated that all six 
subunits are required for the cellular functions of the Elongator complex. These include 
transcriptional activation (8), exocytosis (12), cell migration regulation (13), motor neuron 
degeneration (14), paternal genome demethylation (15), DNA damage response (16) and cell cycle 
regulation (13). Two biochemical activities have been implicated for the Elongator complex: 
histone acetylation and tRNA U34 modification. However, the main biochemical activity 
responsible for the in vivo functions of the Elongator complex has been hotly debated remains 
unresolved.  
To shed light on the biochemical functions of the Elongator complex, we performed a 
bioinformatics search of all six subunits of the human Elongator complex. We found that homologs 
of Elp3, but not Elp1-2 and Elp4-6, are present in essentially all archaea, a small number of bacteria 
and two viruses (Fig. 2.3). Furthermore, all the archaeal and bacterial organisms possessing Elp3 
lack genes encoding MnmE and MnmG, which are responsible for (bacteria) or implicated in 
(archaea) tRNA modification at C5 of U34 (106,115). These revelations, along with the fact that 
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Elp3 possesses a radical SAM and a HAT domain, led us to propose a simple mechanism of tRNA 
U34 modification at C5 that requires only Elp3 for catalysis: a 5′-deoxyadenosyl radical (5′-dA•), 
generated in the radical SAM domain, first abstracts the hydrogen atom attached to C5 of U34 in 
tRNA, which reacts with the methyl group of acetyl-CoA in the HAT domain to form a C-C bond; 
hydrolysis of CoA then results in formation of 5′-carboxymethyluridine (cm5U) (Fig. 3.2).  
  
3.2. Materials and Methods 
 
Cloning, expression and purification of Elp3 
The gene encoding Methanocaldococcus infernus Elp3 (NCBI Protein accession 
code: YP_003616086) was amplified by PCR from Methanocaldococcus infernus genomic DNA 
and inserted into the petDuet-1 vector (Novagen). The plasmid was transformed into 
the Escherichia coli expression strain BL21 (DE3) (Invitrogen). A single colony was used to 
inoculate a starter culture, which was grown overnight at 37°C. This was used to inoculate 1 liter 
of lysogeny broth containing 100 μg/ml ampicillin. Cells were grown at 37°C to A600nm of 
approximately 0.4 and cooled to 18°C. Expression was induced with 0.5 mM 
isopropylthiogalactoside (IPTG). Cells were grown overnight at 18°C and collected by 
centrifugation. The recombinant protein (MinElp3) was purified to homogeneity using DEAE ion 
exchange (DEAE A: 20 mM Tris-HCl pH 8.0, 10 mM NaCl, 2% glycerol, DEAE B: 20 mM Tris-
HCl pH 8.0, 1 mM NaCl, 2% glycerol), heparin affinity (DEAE A and DEAE B buffers), Mono-
Q ion exchange (DEAE A and DEAE B buffers) and Superdex 75 size-exclusion chromatography 
(10 mM HEPES pH 7.0, 200 mM NaCl, 2% NaCl). The C95/98S and Y517A mutants were 
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generated by QuikChange (Stratagene) using the plasmid of Methanocaldococcus infernus Elp3 as 
the template. Purification of the mutants was similar to that of wild-type MinElp3. 
 
Preparation of tRNA substrate  
Methanocaldococcus infernus tRNAArg was in vitro transcribed using T7 polymerase. 
Synthetic DNA oligonucleotides (template strand and a shorter strand complementary to the T7 
promoter) were purified using denaturing PAGE followed by ethanol precipitation. A partially 
double-stranded DNA template was formed by annealing both oligonucleotides together by 
heating at 95 °C for 3 min and cooling slowly. Reaction was performed in 4 mL scale with 0.2 μM 
template, 1.25 mM each NTP, 5 mM DTT and 1 μM T7 polymerase in an in vitro transcription 
buffer containing 40 mM Tris-HCl, pH 7.9, 6 mM MgCl2 and 2 mM spermidine. The reaction was 
incubated at 37 °C overnight, and the transcribed tRNA was purified using denaturing PAGE and 
ethanol precipitation. The recovered tRNA was dried using a SpeedVac and stored at −80 °C. 
tRNA templates are in listed in Table 2.1.  
 
Anaerobic reconstitution of Elp3 activity. 
The [4Fe-4S] of the purified recombinant MinElp3 was chemically reconstituted in an 
anaerobic chamber. Dry chemicals (DTT, (NH4)2Fe(SO4)2, Na2S) were moved into the chamber 
and allowed to equilibrate for ~30 minutes. All chemicals were dissolved and diluted in 
Reconstitution buffer (50 mM HEPES (pH 7.5), 150 mM KCl, 150 mM NaCl and 1% glycerol). 
DTT was first dissolved to 150 mM, followed by a 10x dilution to 5 mM. (NH4)2Fe(SO4)2 was 
dissolved to 150 mM, followed by a 100x dilution. Na2S was dissolved to 150 mM, followed by a 
100x dilution. Overall, the purified MinElp3 was incubated with 3 mM DTT, 300 μM 
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(NH4)2Fe(SO4)2 and 300 μM Na2S in Reconstitution Buffer. Specifically, 200 uL of ~5mg/ml 
MinElp3 was incubated with 100 uL diluted DTT on ice for 15 minutes. Next, 33 uL of diluted 
(NH4)2Fe(SO4)2 was added and incubated on ice for 10 minutes. This was repeated 2 more times. 
Next, 33 uL of diluted Na2S was added and incubated on ice for 20 minutes. This was repeated 2 
more times. The solution was incubated overnight on ice.  
The following day, MinElp3 was desalted using a NAP-5 column (GE Healthcare). 
Specifically, the column was equilibrated 3 times with Reconstitution buffer. Next, 500 uL of 
reconstituted protein was added to the column and 500 uL of Wash 1 was collected. Next, 300 uL 
of Reconstitution buffer was added and 300 uL of Elution 1 was collected. Next, 400 uL of 
Reconstitution buffer was added and 400 uL of Elution 2 was collected. Next, 300 uL of 
Reconstitution buffer was added and 300 uL of Elution buffer was collected. Next, 500 uL of 
Reconstitution buffer was added and 500 uL of Wash 2 was collected. Next, 500 uL of 
Reconstitution buffer was added and 500 uL of Wash 3 was collected. Elution 2 was used for the 
remainder of the experiment. A 10 kDa Ultra-0.5 filter (Amicon) was used to concentrate the 
protein (Elution 2) and perform buffer exchange with Reaction Buffer (50 mM HEPES (pH 7.5), 
150 mM, KCl, 300 mM NaCl, 5 mM MgCl2 and 1% glycerol). 
The in vitro reconstitution reaction was carried out in a 50 μL scale inside the anaerobic 
chamber. tRNAArg was annealed in Reaction Buffer by heating at 90 °C for 3 min and quickly 
cooling on ice. 5 μM MinElp3 was incubated with 5 μM tRNAArg, 50 μM SAM, 50 μM [14C]acetyl-
CoA and 0.5 mM Na2S2O4 in Reaction Buffer at room temperature for 1 h. After the reaction, the 
samples were moved out of the anaerobic chamber, and the tRNA product was recovered by phenol 
extraction followed by ethanol precipitation. The recovered tRNA was dissolved in 10 μL of TE 
buffer. After the addition of gel loading buffer, the samples were analyzed on a 15% denaturing 
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polyacrylamide gel. The gel was dried, and the dried gel was exposed to a PhosphorImaging screen 
(GE Healthcare). The radioactivity was detected by STORM 840 PhosphorImager (GE 
Healthcare). ImageQuant software (GE Healthcare) was used to quantify the radioactive signals. 
To prepare tRNA products for the characterization of the modified nucleoside shown in 
Fig. 3.4, a truncated tRNAArg (with both D and T loops deleted) was employed and the in 
vitro reconstitution reaction described above was scaled up 10 times using unlabeled acetyl-CoA. 
After the reaction, tRNA was recovered with phenol extraction followed by ethanol precipitation. 
To prepare samples for RP-HPLC and ESI-LC/MS analyses shown in Fig. 3.8, the in vitro 
reconstitution reaction was carried out on a 50 μL scale with 100 μM SAM, 100 μM acetyl-CoA, 
50 μM MinElp3 (if necessary), 0.5 mM Na2S2O4 (if necessary) and 50 μM tRNAArg (if necessary) 
in Reaction Buffer at room temperature for 1 h. After the reaction, the sample was filtered by a 10 
kDa Ultra-0.5 filter (Amicon), and the flow-through was analyzed by RP-HPLC or ESI-LC/MS. 
The samples for the experiments shown in Fig. 3.10 were prepared similarly except that no 
Na2S2O4 was added and the reaction time and the concentrations of Elp3 and tRNA were varied 
according to the graphs shown in Fig. 3.10. 
 
Enzymatic reconstitution of [4Fe-FS]  
The [4Fe-4S] of the purified recombinant MinElp3 was enzymatically reconstituted in an 
anaerobic chamber using iscS (Imlay lab, University of Illinois at Urbana-Champaign). 
Specifically, the purified MinElp3 was incubated with 3 mM DTT, 300 μM (NH4)2Fe(SO4)2, 300 
μM L-cysteine and 0.48 uM iscS in Reconstitution Buffer (50 mM HEPES (pH 7.5), 150 mM KCl, 
150 mM NaCl and 1% glycerol). The following day, MinElp3 was desalted using a NAP-5 column 
(GE Healthcare). A 10 kDa Ultra-0.5 filter (Amicon) was used to concentrate the protein and 
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perform buffer exchange with Reaction Buffer (50 mM HEPES (pH 7.5), 150 mM KCl, 300 mM 
NaCl, 5 mM MgCl2 and 1% glycerol). 
 
Preparation of deuterated substrates 
To prepare tRNA substrate with a deuterium at C5 of uridine, d5-uridine-5′-monophosphate 
(d5-UMP) was synthesized using a protocol for the synthesis of d5-uridine (119). In a 1 mL reaction 
scale, 2.5 mM of d5-UMP, 2.5 mM adenosine-5′-triphosphate (ATP), 10 mM 
phospho(enol)pyruvate(PEP), 0.1 unit Nucleoside Monophosphate Kinase (Roche) and 5 units 
Pyruvate Kinase (Sigma) were incubated in Kinase Buffer (80 mM Tris-HCl (pH 7.6), 20 mM 
MgCl2 and 50 mM KCl) at room temperature for 2 hours to produce d
5-uridine-5′-triphosphate (d5-
UTP) and recovered ATP. After reaction, 2.5 mM cytidine-5′-triphosphate (CTP) and 2.5 mM 
guanosine-5′-triphosphate (GTP) were added, and the mixture was directly used for in 
vitro transcription of the deuterated tRNAArg. The deuterated acetyl-CoA (d3-acetyl-CoA) was 
synthesized according to a published procedure (120), and d3-acetyl-CoA was further purified by 
RP-HPLC. 
 
Analysis of reaction products by RP-HPLC and ESI-LC/MS. 
Described in Chapter 2.2. 
 
Continuous-wave EPR  
EPR samples were prepared with 150 μM reconstituted MinElp3, with or without 0.5 mM 
sodium dithionite, in Reconstitution Buffer (50 mM HEPES (pH 7.5), 150 mM KCl, 150 mM 
NaCl and 1% glycerol). CW-EPR experiments were performed on a Varian E-line 122 X-band 
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spectrometer with an Air Products helium cryostat. Data acquisition parameters were: microwave 
frequency = 9.24 GHz, field center = 350.0 mT, field sweep = 100.0 mT, scan time = 60 s, 
modulation frequency = 100 kHz, modulation amplitude = 0.5 mT, time constant = 32 ms, 
temperature = 8 K, 16 scans for each spectrum. 
 
3.3. Results and Discussion 
 
To test our hypothesis on the modification of U34 containing tRNAs by Elp3 (Fig. 3.2), 
recombinant Elp3 from archaeal Methanocaldococcus infernus (MinElp3, Fig. 3.3, 3.4A) was 
cloned, overexpressed and purified and analyzed for the presence of intact [4Fe-4S] (Fig. 3.3). 
Next, the in vitro reconstitution of the modification reaction was performed using 
synthetic MintRNAArg and [14C] acetyl-CoA. In the presence of all components required for the 
reaction, tRNA became radioactive (Fig 3.4B, lane 4), demonstrating the covalent attachment of 
the [14C] acetyl group (or the entire [14C]acetyl-CoA) to tRNA. tRNA was not radiolabeled in the 
absence of Elp3 (3.4b, lane 1), indicating that the reaction requires catalysis by Elp3. When either 
SAM (the source of 5′-dA•) or Na2S2O4 (the reducing agent that provides the electron to generate 
5′-dA•) from the reaction, the tRNA product was not formed (Fig 3.4B, lanes 2 and 3), indicating 
that the reaction occurs via a radical mechanism. Elp3 with a C95S C98S double mutation or a 
Y517A mutation was also inactive (Fig. 3.4B, lanes 5 and 6). When residues equivalent to 
MinElp3 Cys95, Cys98 or Tyr517 were mutated to alanine in Saccharomyces cerevisiae Elp3, 
tRNA U34 modification at C5 was abolished in vivo (16) (Fig. 3.6). Finally, tRNA with a U34C 
mutation was not an effective substrate for the reaction (Fig. 3.4B, lane 7), indicating that U34 is 
the likely site of modification.   
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To gain further insight into the chemical nature of the Elp3-catalyzed reaction, the reaction 
was carried out in a preparative scale and the tRNA product was characterized using RP-HPLC 
and ESI-LC/MS. RP-HPLC analysis of the digested tRNA showed the presence of a new peak in 
addition to the ones belonging to C, U, G and A (Fig. 3.4, bottom). The new peak was absent in 
tRNA from the reaction without Elp3 (Fig. 3.4, top), indicating that it is the product of the Elp3-
catalyzed reaction. Quantification of the peaks indicated that approximately 50% of tRNA 
substrate was converted to product. ESI-LC/MS of the new peak (Fig. 3.3D, left) compared to the 
synthetic compound (Fig. 3.4, right) identified the modified nucleoside as cm5U. This conclusion 
is further supported by the fact that the Elp3-produced product co-eluted with the synthetic 
compound in an RP-HPLC analysis (Fig. 3.7). 
To identify if tRNA or acetyl-CoA is the reacting target of 5′-dA•, the formation of 5′-
dA was analyzed by RP-HPLC (Fig. 3.8A) and the molecular mass (m/z) of 5′-dA in the presence 
of tRNA labeled with deuterium at C5 of U (d5-tRNA) or deuterium-labeled acetyl-CoA (d3-
acetyl-CoA) (Fig. 3.8B) was determined. Surprisingly, the deuterium was found in 5′-dA only 
from the reaction employing d3-acetyl-CoA (Fig. 3.8B, bottom), not the reaction employing d
5-
tRNA (Fig. 3.8B, top), demonstrating that 5′-dA• abstracts a hydrogen atom from acetyl-CoA, 
rather than from tRNA as was initially envisioned. In addition to 5′-dAD, a small but meaningful 
amount of 5′-dAH was also formed in the presence of d3-acetyl-CoA (Fig. 3.8B, bottom). The 
presence of hydrogen atoms is not due to impure acetyl-CoA in the d3-acetyl-CoA sample because 
this was at least 96% pure as judged by ESI-LC/MS (Fig. 3.9, bottom). It may be possible that a 
small amount of 5′-dA• carried out an abortive reaction by abstracting a hydrogen atom from the 
solvent or from amino acids of Elp3 near the SAM-binding pocket.  
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The method in which SAM and acetyl-CoA were consumed also provided insight into the 
mechanism of the Elp3-catalyzed reaction (Fig. 3.8A). In the absence of Elp3, Na2S2O4 and tRNA, 
both SAM and acetyl-CoA were stable over the course of the reaction (Fig. 3.8A, panel 1). 
Addition of Elp3 to the reaction mixture resulted in the consumption of a small but meaningful 
amount of acetyl-CoA, whereas SAM remained intact (Fig. 3.8A, panel 2). Additional experiments 
shown in Fig 3.10A further support the conclusion that Elp3 reacts with acetyl-CoA. These 
observations may have mechanistic implications, as Elp3 may first react with acetyl-CoA to form 
an acetyl-Elp3 covalent intermediate (Fig. 3.11). Addition of Na2S2O4 caused further consumption 
of acetyl-CoA, but still without consumption of SAM (Fig. 3.8A, panel 3). Failure to detect either 
5′-dA or A (Fig. 3.8A, panel 3) indicates that 5′-dA• is not able to form in the absence of tRNA 
despite the presence of all of the chemical ingredients required for the production of 5′-dA•. This 
was confirmed by the detection of 5’-dA when tRNA was added to the reaction (Fig. 3.8A, panel 
4). Surprisingly, addition of tRNA also resulted in complete conversion of acetyl-CoA to 
CoA (Fig. 3.8A, panel 4), indicating that tRNA promotes hydrolysis of acetyl-CoA. This is 
supported by additional experiments showing that only a catalytic amount of tRNA is required to 
rapidly hydrolyze acetyl-CoA (Fig. 3.10B). 
On the basis of the experimental data presented here, the proposed mechanism of the Elp3-
catalyzed reaction is shown in Fig. 3.12. Association of tRNA with Elp3 allows 5′-dA• to be 
generated from SAM in the radical SAM domain of Elp3 (Fig. 3.12, step 1). 5′-dA• then abstracts 
a hydrogen atom from the methyl group of acetyl-CoA bound in the HAT domain of Elp3 (Fig. 
3.12, step 2). The acetyl radical adds to C5 of U34 in tRNA to form a C-C bond (Fig. 3.12, step 
3). Loss of an electron from U34 (Fig. 3.12, step 4), followed by abstraction of the proton at C5 
(Fig. 3.12, step 5), results in formation of the tRNA-acetyl-CoA conjugate. Hydrolysis of 
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CoA produces the modified nucleotide cm5U at the wobble position of tRNA (Fig. 3.12, step 6). 
In the absence of tRNA, the Elp3-bound acetyl-CoA is stable; association of tRNA with 
Elp3 results in hydrolysis of acetyl-CoA (Fig. 3.12, step 7). Unresolved issues include the identity 
of the general base that abstracts the proton at C5, the molecular mechanism by which tRNA 
promotes generation of 5′-dA• and the molecular mechanism by which tRNA catalyzes hydrolysis 
of CoA from either acetyl-CoA or the tRNA–acetyl-CoA conjugate. In addition, some of our 
experimental data (Fig. 3.10 is an example) appeared to indicate the formation of an acetyl-
Elp3 covalent intermediate during the Elp3-catalyzed reaction, but we were not able to obtain 
convincing evidence to verify this. Therefore, a reaction mechanism involving an acetyl-
Elp3 covalent intermediate, as shown in Fig. 3.11, cannot be ruled out. In such a mechanism, 
hydrolysis of CoA would be the first rather than the last step of the reaction, and an Elp3-tRNA 
covalent intermediate would be formed over the course of the reaction. 
It is interesting to compare the Elp3-catalyzed reaction with the one catalyzed by RlmN and 
Cfr, which are responsible for the methylation of A2503 at C2 and C8 in 23S ribosomal RNA 
(122). Both Elp3 and RlmN/Cfr employ a radical mechanism, and in both cases 5′-dA• reacts first 
with the donors of the modification (acetyl and methyl groups, respectively) despite having the 
opportunity to first react with the RNA base. Thus, 5′-dA• might not be able to generate a radical 
on a carbon atom with sp2 hybridization and this has not yet been observed to date (122). In 
addition, if Elp3 catalyzes tRNA modification through an acetyl-Elp3 covalent intermediate (Fig. 
3.11), the overall sequence of reactions carried out by Elp3 is essentially the same as the one 
carried out by RlmN/Cfr except for the major difference in loading the donors of the modifications. 
It is also interesting to compare the chemistry carried out by Elp3 with the chemistry 
carried out by CmoA and CmoB, which also perform tRNA wobble uridine modification at C5 in 
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Gram-negative bacteria (112). Both systems transfer a carboxymethyl group from a cofactor to 
U34, but they employ different chemistry. A comparison of the components required for the two 
systems demonstrates the greater efficiency of the Elp3-catalyzed reaction, which requires only 
one protein and two of the most common cofactors (SAM and acetyl-CoA). 
As Elp3 is highly conserved between archaea and eukarya (Fig. 3.6; MinElp3 is 44% and 
45% identical to human and yeast Elp3, respectively), Elp3 in the eukaryotic Elongator complex 
is likely to be solely responsible for the chemistry of the tRNA modification reaction. If this is the 
case, the functional characterization of Elp3 reported here, along with the evidence that the 
Elongator complex is present mainly in the cytoplasm (20,123,124, 125), supports the view that 
tRNA U34 modification at C5 is the ancient and primary biochemical function of the Elongator 
complex. In addition, the mechanistic insight provided into the mode of action of Elp3 indicates 
that the primary role of the C-terminal HAT domain of Elp3 is to provide an acetyl-CoA for tRNA 
modification, not for histone acetylation. 
 
Substrate Specificity of MinElp3 
To understand substrate specificity, MintRNALys, MintRNAThr and a series of truncated 
tRNAs (based on the MintRNAArg sequence) were in vitro transcribed. A preliminary study of the 
minimum requirement of RNA substrate was done by performing an in vitro reconstitution with 
these substrates. Compared to the wild-type MintRNAArg, there was a lower efficiency in acetyl-
CoA incorporation for all of the truncations and the stem loop had the least efficiency. MintRNALys 
and MintRNAThr had an efficiency similar to that of MintRNAArg (Fig. 3.13). Since Elp3 is still 
able to modify these RNA species, it may be possible that the other subunits in the eukaryotic 
Elongator complex aid in selecting only full length tRNAs. This data provides us with guidance 
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for sample preparation for structural study of the Elp-tRNA complex, which is discussed in 
Chapter 5. 
 
Chemical and Enzymatic reconstitution of [4Fe-4S] 
 A preliminary study on [4Fe-4S] assembly was performed using iscS, a cysteine 
desulfurase from Escherichia coli. iscS uses cysteine as an source of sulfur to assemble and insert 
the [4Fe-4S] into [4Fe-4S] proteins (126). Following reconstitution of the cluster, an in vitro 
reconstitution reaction using MintRNAArg was performed which indicated that the efficiency of 
the tRNA modification reaction with iscS was comparable (Fig 3.14, lane 2) to the reaction 
performed with chemically reconstituted cluster (Fig. 3.14, lane 7). Further analysis is required to 
systematically determine the efficiency of the reaction with the iscS reconstituted cluster.    
 
Pursuing the identification of a tRNA-Elp3 covalent intermediate 
Some data (for example, Fig. 3.10) indicated the formation of a covalent intermediate. Fig. 
3.11 describes the proposed mechanism of the Elp3-catalyzed reaction with a covalent 
intermediate. To study this further, 10 nucleophilic residues, which were highly conserved in 600 
Elp3, were identified across the radical SAM, HAT and Connector (the highly conserved region 
between the radical SAM and HAT domains) domains. These residues were mutated to alanine 
using MinElp3 as the template. The proteins were overexpressed and purified similarly to wild-
type MinElp3. Next, an in vitro reconstitution reaction was performed using radiolabeled acetyl-
CoA and MintRNAArgUCU. The tRNA was isolated and analyzed for D-PAGE and reduced activity 
was identified in 4 of the mutants, indicating inefficient incorporation of the acetyl group on tRNA. 
The proteins were analyzed on SDS-PAGE, and these 4 mutants displayed relatively higher 
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radioactivity, indicating that the acetyl group is still bound to Elp3. Further analysis is required to 
identify a potential covalent intermediate for crystallization.  
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3.4. Figures 
 
       
Fig. 3.1. Composition of the Elongator complex and chemical structures of the modified wobble 
uridine at C5 in cytoplasmic tRNAs of eukaryotic organisms. A. Schematic view of the six subunits 
of human Elongator complex. Only the domains of the catalytic subunit, Elp3, are defined and 
highlighted in color. In Elp3, the radical S-adenosylmethionine (SAM) domain is colored orange, 
and the histone acetyltransferase (HAT) domain is colored red. In addition to these two domains, 
the N-terminal domain (colored blue), which is the least conserved in Elp3, is rich in lysines and 
arginines (KR). The KR domain might be involved in tRNA substrate binding due to the presence 
of many positively charged residues. The region connecting radical SAM and HAT domains 
(colored cyan) is also highly conserved, but its biochemical function is unknown. B. Chemical 
structures of the modified uridines at C5 that require catalysis of the Elongator complex. 5-
methoxycarbonylmethyluridine (mcm5U) and 5- carbamoylmethyluridine (ncm5U) are two 
modified nucleotides found in approximately 25% of cytoplasmic tRNAs in eukaryotic organisms. 
They are formed through the intermediate 5-carboxymethyluridine (cm5U), which is catalyzed by 
the Elongator complex based on genetic studies. 
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Fig. 3.2. Preliminary proposed mechanism for the synthesis of mcm5U and ncm5U. 
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Fig. 3.3. Evaluation of the purified recombinant MinElp3. A. SDS gel analysis of both wild-type 
and mutated Elp3. Each protein was analyzed before and after reconstitution of [4Fe-4S]. SM, size 
marker. B. UV-vis spectra of purified wild-type MinElp3 before (blue) and after (red) 
reconstitution of [4Fe-4S]. The shoulder indicated by an arrow shows the presence of [4Fe-4S]. 
The bumps marked with asterisks are artifacts of the UV-vis spectrometer, presumably caused by 
transition from vis to UV lights. C. EPR spectra of purified reconstituted MinElp3 (150 µM) treated 
without (blue) and with (red) sodium dithionite (500 µM). 
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Fig. 3.4. A. Schematic view of the domain structure of MinElp3, similar to the structure for human 
Elp3 shown in Fig. 1.2. The CxxxxCxxC motif that coordinates [4Fe-4S] is highlighted. B. 
Denaturing PAGE analysis of tRNA products from the Elp3-catalyzed reactions. SM, size markers. 
C. RP-HPLC chromatograms of the digests of tRNA products from the reactions without (top) and 
with (bottom) Elp3. The Elp3-produced product cm5U is indicated by an arrow. D. ESI-LC/MS 
analyses of cm5U from the Elp3-catalyzed reaction (left) and the synthetic compound (right). 
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Fig. 3.5. A broader view of DPAGE analysis of the Elp3-catalyzed reactions. The image shown in 
Fig. 3.4 is the cropped version of the image displayed here. 
 
 
Fig. 3.6. Conservation of Elp3 from eukarya to archaea. Amino acid sequences of Elp3 from 
Methanocaldococcus infernus (MinElp3), human (HsaElp3), and Saccharomyces cerevisiae 
(SceElp3) were aligned. The conserved residues are boxed in color, with completely conserved 
residues in magenta, identical residues in yellow, and similar residues in cyan. Residue numbers 
above the alignment corresponds to MinElp3, and those below belong to SceElp3. Three mutations 
in MinElp3 used for this study are marked with asterisks. 
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Fig. 3.7. Co-elution of the modified nucleoside produced by Elp3 with the synthetic cm5U. RP-
HPLC chromatograms of synthetic cm5U (panel 1), the digests of tRNA product of the Elp3-
catalyzed reaction (panel 2), and a mixture of the two (panel 3). 
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Fig. 3.8. A. RP-HPLC chromatograms of the reactions differing in components, starting with the 
one containing only the cofactors (SAM and acetyl-CoA) in the reaction buffer (panel 1). Missing 
components were added one at a time (panels 2 and 3) until all the components required for the 
reaction were included (panel 4). B. ESI-LC/MS analyses of the resulting 5′-dA from the reactions 
in the presence of the deuterated tRNA (top) and the deuterated acetyl-CoA (bottom). 
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Fig. 3.9. ESI-LC-MS analyses of acetyl-CoA (top) and d3-acetylCoA (bottom) from the same 
reaction samples that generated 5’-dAH and 5’-dAD shown in Fig. 3.8B. The purity of d3-acetyl-
CoA is at least 96% based on the analysis shown in the bottom panel. 
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Fig. 3.10. Consumption of acetyl-CoA by Elp3 and hydrolysis of acetyl-CoA in the presence of 
tRNA. A. Consumption of acetyl-CoA was plotted against the concentration of Elp3. The plot 
shows a linear relationship between the consumption of acetyl-CoA and the concentration of Elp3. 
In several experiments, the amount of acetyl-CoA consumed by Elp3 was between 1/4 and 1/3 of 
the amount of Elp3 used. The solution of the flow-through from the Ultra-0.5 filter of the final step 
preparation of Elp3, which should have the same composition as the solution of Elp3 minus the 
protein, did not consume any acetyl-CoA, indicating that the acetyl-CoA was consumed by Elp3 
or substance(s) associated with Elp3. Furthermore, Elp3 without [4Fe-4S] reconstitution behaved 
the same, indicating [4Fe-4S] is not responsible for the consumption of acetyl-CoA. B. 
Consumption of acetyl-CoA was plotted against the reaction time. In the absence of tRNA, a small 
amount of acetyl-CoA was rapidly consumed by Elp3 but the consumption leveled off over time. 
Addition of a small amount of tRNA resulted in further hydrolysis of acetyl-CoA, and the rate of 
hydrolysis was dependent on the concentration of tRNA. The concentration of Elp3 for these 
experiments was 20 µM. 
 
 57 
 
 
Fig. 3.11. An alternative mechanism of the Elp3-catalyzed reaction that involves the formation of 
an acetyl-Elp3 covalent intermediate. In this mechanism, Elp3 first reacts with acetyl-CoA located 
in the HAT domain to form an acetyl-Elp3 covalent intermediate (step I), which is stable in the 
absence of tRNA. Association of tRNA with Elp3 results in hydrolysis of the acetyl group, whether 
it is covalently linked to Elp3 alone or to both Elp3 and tRNA (steps VIII, VII). Also, an Elp3-
tRNA covalent intermediate, bridged by the acetyl group, is formed over the course of reaction 
(step VI). The reactions of the remaining steps are very similar to the ones shown in Fig. 3.12, 
with the exception of acetyl-Elp3 covalent intermediate replacing acetyl-CoA. 
 
 
Fig. 3.12. Proposed mechanism for the Elp3-catalyzed reaction.  
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Fig. 3.13. Substrate specificity of MinElp3. 
 
                                                 
Fig. 3.14. In vitro reconstitution of the tRNA U34 modification using enzymatically reconstituted 
[4Fe-4S]. Lane 2: In vitro reconstitution reaction performed with enzymatically reconstituted 
protein. Lane 7: In vitro reconstitution reaction performed with chemically reconstituted protein.  
 
   1         2          3         4           5         6         7 
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Fig. 3.15. Identification of a covalent Elp3-tRNA intermediate. MintRNAArg extracted from in 
vitro reconstitution reaction (top gel). SDS-PAGE gel of MinElp3 following in vitro reconstitution 
reaction (bottom gel).  
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CHAPTER 4: MOLECULAR BASIS OF TRNA WOBBLE URIDINE MODIFICATION 
BY ELP3 
 
4.1. Introduction 
 
The Elongator complex consists of two subcomplexes: one consists of Elp1-3 and the other 
consists of Elp4-6. Elp 1 is ~150kDa (in Saccharomyces cerevisiae) and is the largest of the six 
subunits. It has two WD40 β-propeller domains at the N-terminus and a tretratricopeptide repeat 
(TPR) domain at the C-terminus. WD40 proteins play the role of scaffolding proteins that facilitate 
activity and function of proteins and assist in protein-protein and protein-nucleic acid interactions. 
They have not been shown to have catalytic activity; however, they have additional domains with 
catalytic or other functional activities (127). These proteins participate in diverse functions 
including signal transduction, cell division, cytoskeleton assembly, chemiotaxis and RNA 
processing. Each WD40 repeat (blade) consists of a four-stranded antiparallel β-sheet (Fig. 4.1). 
Most structurally characterized WD40 proteins contain seven blades folded into a seven-bladed β-
propeller (128). Thus, Elp1 may stabilize the entire Elongator complex by acting as a scaffold for 
the other Elongator proteins. 
Mutations in Elp1 has been associated with a neurodegenerative disease known as familial 
dysautonomia (FD). FD patients carry a non-coding point mutation which results in a tissue-
specific exon skipping event which leads to the production of a truncated Elp1. It has been 
suggested that the decrease in wild-type Elp1 results in the observed phenotypes (67).  
Elp2 (~90kDa in Saccharomyces cerevisiae) is the second largest subunit of the complex. 
The Elp2 deletion is yeast displays phenotypes identical to the Elp1 deletion in Saccharomyces 
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cerevisiae (41). It is predicted to have two seven-bladed WD40 domains, with a total of fourteen 
WD40 repeats (129). The role of Elp2 has not been well established; however, the presence of the 
WD40 domains suggest a role as a scaffolding protein.    
Elp3 (~65kDa in Saccharomyces cerevisiae)  is considered the catalytic subunit of the 
Elongator complex and the studies presented in Chapter 3 discuss the likely role of Elp3 in being 
solely responsible for the modification reaction in archaeal and bacterial species that only have 
Elp3 (and no other subunits). However, genetic studies have shown that all six subunits are 
required for the cellular activities of the Elongator complex. Thus, it may be possible that the main 
and evolutionarily ancient function of the Elongator complex was in tRNA modification, and it 
acquired additional biochemical functions by recruiting other subunits.  
The structure of Elp4-6 was recently solved at 2.1 Å resolution. The crystal structure 
revealed that all 3 subunits share a RecA-like fold and two heterotrimers form a hexameric ring-
like structure. Thus, it may be possible that the entire Elongator complex could be as large as ~850 
kDa, assuming that each hexameric Elp4-6 sub-complex interacts with two copies of the Elp1-3 
core complex (Fig. 4.2). RecA-like ATPases bind DNA or RNA substrates with nucleotides 
regulating the movement of the substrates (130). The Elp4-6 subcomplex was shown to bind the 
anticodon loop of tRNA in the central cavity of the hexameric ring. Also, ATP hydrolysis regulates 
tRNA binding and release. (131).  
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4.2. Materials and Methods 
 
Cloning, expression and purification of Elp3  
Elp3 clones and mutants are listed in Table 4.1. Plasmids were transformed into 
the Escherichia coli expression strain BL21 (DE3) (Invitrogen). A single colony was used to 
inoculate a starter culture, which was grown overnight at 37 °C. This was used to inoculate 1 liter 
of lysogeny broth containing 100 μg/ml ampicillin. Cells were grown at 37 °C to A600nm of 
approximately 0.4 and cooled to 18 °C. Expression was induced with 0.5 mM 
isopropylthiogalactoside (IPTG). Cells were grown overnight at 18°C and collected by 
centrifugation. The non-His tagged recombinant protein was purified to homogeneity using DEAE 
ion exchange (DEAE A: 20 mM Tris-HCl pH 8.0, 10mM NaCl, 2% glycerol, DEAE B: 20 mM 
Tris-HCl pH 8.0, 1mM NaCl, 2% glycerol), heparin affinity (DEAE A and DEAE B buffers), 
Mono-Q ion exchange (DEAE A and DEAE B buffers) and Superdex 75 size-exclusion 
chromatography (10 mM HEPES pH 7.0, 200 mM NaCl, 2% glycerol). His-tagged recombinant 
protein was purified using Nickel affinity (Ni A: 20 mM Tris-HCl pH 8.0, 100 mM NaCl, Ni B: 
20 mM Tris-HCl pH 8.0, 100 mM NaCl, 500mM Imidazole), heparin affinity, Mono-Q ion 
exchange and Superdex 75 size-exclusion chromatography.  
 
Crystallization, data collection and structure determination 
Crystals of 6xHis-MinElp3 C95/98S mutant were grown by the hanging-drop vapor 
diffusion method at 4°C. The purified protein (~7 mg/mL) was mixed with a reservoir solution 
containing 14-16% PEG3350, 100 mM sodium chloride, 220 mM sodium citrate pH 6.4 (different 
shape was obtained by adding 4% butanol). Needle-like crystals appeared after 3-7 days. Longer 
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crystals with less twin were obtained from the non-his tag version of the same protein under similar 
conditions. Crystals were soaked briefly in a cryo-protection solution containing all of the 
components of the reservoir solution supplemented with glycerol, and the cryo-protected crystals 
were mounted in a nylon loop and flash-frozen in liquid nitrogen. Data was collected at the 21-ID 
beam line at the Advanced Photon Source (APS) and processed using the HKL2000 program. 
Phase was determined based on a SeMet SAD data using the Phenix program. A partial model was 
automatically built using Phenix. The remaining model was manually built using the Coot 
program. Refinement was done using Phenix.  
 
Isolation of tRNAs bound to protein (from FPLC elution fractions) 
300 uL phenol:chloroform (pH 6.6) was added to 300 uL protein sample (Note: Unbuffered 
phenol was not used as in whole cell extraction as it is too harsh for this separation). Samples were 
spun at 9.5 RPM for 5 minutes. Top layer was removed (avoiding layer in between) and added to 
a separate 2 mL tube. 1/10th the volume (30 uL) of 3 M sodium acetate (pH 5.2) was added, 
followed by 2.5x volume 100% cold ethanol. Samples were cooled on dry ice for 20 minutes. Next, 
samples were centrifuged at 12,000 RPM for 20 minutes. The pellet was air dried in the hood for 
3-5 hours until the pellet is fully dried. The pellet was re-suspended in DEPC H2O or TE pH 7. 
Equal volume of annealing buffer (5 mM NaCl, 5 mM MgCl2) was added, heated for 3 minutes at 
95 °C and cooled on ice for 10 minutes. Samples were analyzed on 2% agarose gel.  
 
Gel mobility shift assay 
Sigmacote was used to buff the glass plates. Plates were sealed and gel was cast with 8% 
gel solution (5.3 mL 30% acrylamide, 10 mL 1x TBE, 4.7 mL H20, 200 uL APS, 20 uL TEMED). 
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Reaction was incubated for 1 hour at 37 °C and 2 uL 80% glycerol was added to each sample. Gel 
was run for 1 hour at 80 V using 1x TBE buffer. RNA was visualized using EtBr solution. Protein 
was visualized using commassie blue staining solution.  
 
2D-PAGE analysis 
A semi-thin 10% gel was made for the first dimension using the UreaGel system (10 mL 
concentrate, 12.5 mL diluent, 2.5 ml buffer, 125 uL APS, 12.5 mL TEMED). Gel was pre-run for 
2 hours at 3 Watts. DPAGE gel loading dye was added and the samples were heated at 95 °C for 
3 minutes followed by cooling on ice for 10 minutes. The gel was visualized using EtBr solution. 
Bands were cut, flipped -90° and attached horizontally to a 20% semi-thin gel (15 mL 40% 
acrylamide 19:1, 3 mL 10x TBE buffer, 5.8  g urea, 7.5 mL H20, 120 ul APS, 12 ul TEMED) 
(Note: spacers were covered with tape to create a slightly thicker gel). 10% gel solution (1 mL 
concentrate, 1.25 mL diluent, 0.25 mL buffer, 25 uL APS, 2.5 uL TEMED) was used to seal the 
gel strip to the 20% gel. Gel was run overnight at 3 W in the 4 °C cold room (~16 hours). Gel was 
visualized using EtBr solution. 
 
Elp3-tRNA complex for size-exclusion chromatography and structural studies  
The purified tRNA pellet was re-suspended in GF buffer + MgCl2 (10 mM HEPES pH 7.0, 
200 mM NaCl and 2% glycerol, 5 mM MgCl2). tRNA was annealed by heating for 3 minutes at 
95 °C and cooling on ice for 10 minutes. tRNA was then purified using size-exclusion 
chromatography. The collected fractions were incubated with Elp3 for ~20 minutes and analyzed 
via size-exclusion chromatography.  
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Limited protease digestion 
1 mg/ml trypsin and chymotrypsin were prepared in GF buffer (10 mM HEPES pH 7.0, 
200 mM NaCl, 2% glycerol). Various dilutions of trypsin and chymotrypsin were prepared in GF 
buffer. 1 uL of enzyme was added to 5 uL of protein sample (used collected fraction from gel 
filtration) in 20 uL total volume. The reaction was incubated at room temperature for 1 hour. 
Samples were analyzed on SDS-PAGE. The reaction was scaled up and purified using size-
exclusion chromatography.  
 
Total tRNA isolation, isolation of specific tRNAs using single-stranded biotinylated DNA, in 
vitro transcription and purification 
Described in Chapter 2.2.  
 
4.3. Results and Discussion 
 
Cloning and purification of Elp3 
To identify Elp3 for biochemical and structural studies, a BLASTp search was performed 
using human Elp3 (HsaElp3) as the seed against archaeal genomes. At the time of the study, the 
top four hits were from Methanocaldococcus infernus (MinElp3), Methanotorris igneus 
(MigElp3), Methanocaldococcus jannaschii (MjaElp3) and Methanocaldococcus fervens 
(MfeElp3); these were cloned into the petDuet vector with and without the His-tag.  
Full length and various truncations of these sequences were cloned and purified. Apart 
from thee 4 archaea, Elp3 (with and without his-tag) was also cloned from Sulfolobus solfataricus 
(Archaea, SsoElp3), Theroplasma acidophilum (Archaea, TacElp3) and Acanthamoeba castellanii 
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(Eukarya, AcaElp3). For co-expression studies, Elp2 and Elp3 from Saccharomyces cerevisiae 
(SceElp2, SceElp3) and from Homo sapiens (HsaElp2, HsaElp3) were cloned into the petDuet 
vector (no expression was detected).  
Elp3 was also cloned (His-tag and non-His-tag) and purified from Methanocorpusculum 
labreanum (MlaElp3), Methanoculleus marisnigri (MmaElp3), Methanohalobium evestigatum 
MevElp3), Methanothermococcus okinawensis (MokElp3), Methanocaldococcus vulcanius 
(MvuElp3) and Methanotorris formicicus (MfoElp3).   
The best expression, protein purity/stability and only positive signs of crystallization was 
detected with Elp3 from Methanocaldococcus infernus (MinElp3, E = 2e-158, 44% identical to 
HsaElp3), and this construct was heavily pursued for biochemical and structural studies. The 
primers used for cloning and the results of the cloning and purification process for the Elp3 
constructs are listed in Table 4.1. Fig. 4.3 is an example of the purification steps from DEAE (anion 
exchange) through gel filtration (size exclusion) of Non-his tag wild-type MinElp3. 
 
Structural studies on MinElp3 
 Protein was purified from all species listed above and no positive signs of crystallization 
were observed initially. This may have been due to loss of the [4Fe-4S] due to purification under 
aerobic conditions, which may cause aggregation due to disulfide bond formation in the CX4CX2C 
motif. The [4Fe-4S] of MinElp3 was chemically and enzymatically reconstituted inside the 
chamber and set up for crystallization – however, no crystals were obtained.  
To address this issue, the second and third cysteines in the CX4CX2C motif were mutated 
to serines. Crystals with and without selenomethionine were obtained from MinElp3 C95/98S 
mutant (Fig. 4.4). The crystals diffracted to 3.2 Å; however, the structure could not be solved 
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because the crystals were twinned. Small crystals were obtained from the wild-type MinElp3 using 
optimized crystallization conditions.  
A low resolution structure was obtained, which was partially built using alanine and 
glycine residues (Fig. 4.5). Based on the location of the selenomethionine residues, the domains 
were roughly identified (the region connected the radical SAM and HAT domain has not been 
labeled). The N-terminal domain is identified in blue, the HAT domain in red and the radical SAM 
domain in yellow. The side view (Fig. 4.5, right), shows that the N-terminal domain is L-shaped 
like tRNA. Since this is the lysine-arginine rich region, it may be involved in tRNA binding.  
The surface view (Fig 4.6) allows a clearer view of the channel. This is a true channel as 
there is no density in this area. Overall, the structure suggests that after the tRNA binds the cleft, 
the anticodon loop enters the channel from one side and SAM and acetyl-CoA enter from the other 
side shown in Fig. 4.6B. The radical is generated in the radical SAM domain, which then abstracts 
a hydrogen atom from the methyl group of acetyl-CoA bound to the HAT domain of Elp3.  
Using phasing information from a recently published structure of Elp3 from 
Dehalococcoides mccartyi, we were able to solve the structure of MinElp3 (Fig. 4.7). The radical 
SAM domain (Fig. 4.7, green) has a TIM barrel fold with alternating alpha-helices and beta-
strands. The HAT domain (Fig. 4.7, purple) has a pocket for acetyl-CoA binding. The structure 
suggests that there is a ~20Å distance between C5 of SAM and the methyl group of acetyl-CoA. 
A highly conserved lysine residue is positioned close to acetyl-CoA, which may be involved in 
forming a covalent intermediate with acetyl-CoA, followed by serving as an arm to allow the 5’-
dA• to react with the methyl group of acetyl-CoA.     
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Limited protease digestion of MinElp3 
In order to determine a stable domain of Elp3 that may be favorable for crystallization, 
MinElp3 was subjected to limited protease digestion by trypsin and chymotrypsin (Fig. 4.8). 
Digestion with trypsin (Fig. 4.8, lane 5, 50x dilution of 1 mg/ml) produced a fragment of ~ 35kDa. 
A similar sized fragment was also identified with chymotrypsin (Fig. 4.8, lane 8, 50x dilution of 1 
mg/ml). Both fragments were successfully purified; however, no crystals were obtained.    
 
Elp3 binds specific tRNAs in vivo 
During the purification of all non-his tag versions of Elp3 using DEAE anion exchange, a 
significant amount of protein did not bind the column and was found in the flow-through (despite 
the use of differing salt concentrations and various buffers). The same results were observed when 
the SP cation exchange column was used. To determine if other Escherichia coli components were 
binding to Elp3 to prevent it from binding the column, the His-tag version of MjaElp3 was purified 
using a Nickel column to allow all MjaElp3 species to be bound to the column. The UV λmax was 
260 nm, indicating the presence of nucleic acids. The nucleic acids were isolated from the fractions 
bound to Elp3 and the modification and analyzed via an agarose gel. Total tRNAs isolated from 1 
L E.coli cells and in vitro transcribed MintRNAArg were also analyzed. The results indicated that 
the bound species were tRNAs (Fig. 4.9). Similar results were obtained with MinElp3. 
To further understand the Elp3-tRNA interaction in Escherichia coli, we performed two-
dimensional polyacrylamide gel electrophoresis of the tRNA bound to Elp3 and total Escherichia 
coli tRNAs. With the exception of “spot” 7, spots corresponding to the major species of the Elp3-
bound tRNAs (Fig.  4.10, right panel) were located on the gel of total tRNAs (Fig. 4.10, left panel). 
Of the seven major species, tRNAs corresponding to 2, 4 and 6 are significantly enriched, 
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indicating that Elp3 significantly prefers these three tRNAs. Overall, the results demonstrated that 
MjaElp3 prefers to bind a certain subset of E.coli tRNAs. The same results were obtained with 
MinElp3 (Fig. 4.11). These tRNA-Elp3 interactions were confirmed by gel mobility shift assays.  
 
Elp3 binds specific tRNAs in vitro 
To further understand the interaction between Elp3 and tRNA, MintRNAArgUCU was in vitro 
transcribed, gel purified, purified using size-exclusion chromatography and incubated with 
recombinant MinElp3. The mixture was then analyzed via size-exclusion chromatography. A shift 
in the chromatographic retention volume was observed when compared to MintRNAArgUCU or 
MinElp3 alone (Fig 4.12), indicating the formation of a stable MinElp3-tRNAArgUCU complex. The 
retention volume of the complex indicates a heterodimer. Similar results were obtained with in 
vitro transcribed MintRNALysUUU and MintRNA
Thr
UGU. Similar results were also obtained with 
truncated versions of these tRNAs, in which 3-4 bases were removed from the 3’ end of the tRNA 
in order to form a “flat top” (i.e. the first base at the 5’ end base pairs with the last residue at the 
3’ end).   
Similar results were also obtained when MinElp3 was incubated with Escherichia coli 
tRNAs EcotRNAGluUUC, EcotRNA
Ala
UGC, EcotRNA
Leu
UAG and EcotRNA
Thr
UGU, which were 
purified using the single-stranded biotinylated DNA method described in Chapter 3. Escherichia 
coli tRNAs which were enriched in Figs. 4.11 and 4.12 were also were purified in a larger scale 
using the 2D-PAGE technique. This was then subject to the same analysis which revealed similar 
results. Various combinations of MjaElp3, MinElp3 and MinElp3 C95/95S were incubated with 
these various forms of tRNAs for crystallization; however, no positive signs of crystals were 
obtained. To study this further, various tRNAs were incubated with MinElp3 and aged for a week. 
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The tRNAs were then analyzed on D-PAGE and the results revealed that the tRNAs were 
degrading, despite extensive efforts to reduce exposure to RNases.  
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4.4. Figures and Tables: 
 
                                                  
Fig. 4.1. Structural features of WD40 proteins (128). 
               
Fig. 4.2. Structural models of Elp1, Elp2, Elp3, Hrr25, Kti11, Kti12 and Kti13 around the crystal 
structure of Elp456 (132). 
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Fig.4.3. SDS-PAGE of purification of MinElp3. U: uninduced sample, I: IPTG induced sample, 
supernatant, FT: flowthrough, DEAE: DEAE anion exchange, H: Heparin affinity, MQ: Mono Q 
anion exchange, GF: gel filtration. 
 
 
                 
Fig. 4.4. Crystallization and X-ray diffraction of MinElp3 C95S/C98S mutant. A. Image of the 
initial crystals of the MinElp3 mutant. B. A quarter of an X-ray diffraction image from a fragment 
of an initial crystal shown in A. Arrow points to the detectable spot with highest resolution. C. 
Image of the improved crystals.  
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Fig. 4.5. Partial build of MinElp3. Blue: N-terminal domain, Red: HAT domain, Yellow: radical 
SAM domain.  
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Fig. 4.6. A. Space filling partial build of MinElp3. Blue: N-terminal domain, Red: HAT domain, 
Yellow: radical SAM domain. B. Front view of channel C. Back view of channel 
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Fig. 4.7. Structure of MinElp3 with radical SAM domain depicted in green and HAT domain in 
purple. 
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Fig. 4.8. SDS-PAGE analysis of trypsin (2-5) and chymotrypsin (6-9) digested MinElp3. Lane 1: 
MinElp3, 2: 400x, 3: 200x, 4: 100x, 5:50x, 6: 200x, 7: 100x, 8:50x, 9:20x, 10: Ladder 
 
 
 
                                 
Fig. 4.9. Agarose gel analysis of nucleic acids associated with MjaElp3. Lane 1, total Escherichia 
coli RNAs; lane 2: Elp3-bound RNAs; lane 3, in vitro transcribed MintRNAArg.  
 
   1     2     3     4      5    6     7     8      9   10 
35 kDa 
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Fig. 4.10. 2D PAGE analysis of total Escherichia coli tRNAs (left panel) and the MjaElp3-bound 
tRNAs (right panel).  
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Fig. 4.11. Left: First dimension. Right: Second dimension: 2D PAGE analysis of total Escherichia 
coli tRNAs (left panel) and the MinElp3-bound tRNAs (right panel).  
 
 
                                     
Fig. 4.12. Size exclusion chromatography of MinElp3 (blue), MintRNAArg (green) and the tRNA-
Elp3 complex (red). 
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Table 4.1. 
Organism Versions cloned Notes 
Methanocaldococcus jannaschii, 
full length 
His tag, non-his tag petDuet, Amp resistance for his and 
non-his 
Methanocaldococcus jannaschii 
1-71 
His tag, non-his tag petDuet, Amp resistance for his and 
non-his 
Methanocaldococcus jannaschii 
1-79 
His tag, non-his tag petDuet, Amp resistance for his and 
non-his 
Methanocaldococcus jannaschii 
1-50 
His tag, non-his tag petDuet, Amp resistance for his and 
non-his 
Methanocaldococcus jannaschii 
1-61 
His tag, non-his tag petDuet, Amp resistance for his and 
non-his 
Methanocaldococcus infernus, 
full length  
His tag, non-his tag petDuet, Amp resistance for non-his, 
pet28b, Kan resistance for his 
Methanocaldococcus infernus, 
1-65 
His tag, non-his tag petDuet, Amp resistance for non-his, 
pet28b, Kan resistance for his 
Methanocaldococcus infernus, 
1-73 
His tag, non-his tag petDuet, Amp resistance for non-his, 
pet28b, Kan resistance for his 
Methanocaldococcus fervens, 
full length 
His tag, non-his tag petDuet, Amp resistance for his and 
non-his; insoluble 
Methanotorris igneus, full length His tag, non-his tag petDuet, Amp resistance for his and 
non-his; insoluble 
Sulfolobus solfataricus, full 
length 
His tag, non-his tag petDuet, Amp resistance for his and 
non-his; insoluble 
Thermoplasma acidophilum, full 
length 
His tag, non-his tag petDuet, Amp resistance for his and 
non-his 
Acanthamoeba castellanii, full 
length 
His tag, non-his tag petDuet, Amp resistance for his and 
non-his 
Methanocorpusculum 
labreanum, full length 
His tag, non-his tag petDuet, Amp resistance for his and 
non-his, soluble with ice 
Methanoculleus marisnigri, full 
length 
His tag, non-his tag petDuet, Amp resistance for his and 
non-his 
Methanohalobium evestigatum, 
full length 
His tag, non-his tag petDuet, Amp resistance for his and 
non-his 
Methanothermococcus 
okinawensis, full length 
His tag, non-his tag petDuet, Amp resistance for his and 
non-his 
Methanocaldococcus vulcanius 
M7, full length 
His tag, non-his tag petDuet, Amp resistance for his and 
non-his, low expression 
Methanotorris formicicus, full 
length 
His tag, non-his tag petDuet, Amp resistance for his and 
non-his, low expression 
Saccharomyces cerevisiae, full 
length Elp2 and Elp3 
His tag, non-his tag petDuet, Amp resistance for his and 
non-his, no expression 
Homo sapiens full length Elp2 
and Elp3 
His tag, non-his tag petDuet, Amp resistance for his and 
non-his, no expression 
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Mutants: 
Methanocaldococcus infernus 
C95/98S 
His tag, non-his tag petDuet, Amp resistance non-his; 
pet28b, Kan resistance for his 
Methanocaldococcus infernus 
C90/95/98S 
His tag, non-his tag petDuet, Amp resistance non-his; 
pet28b, Kan resistance for his 
Methanocaldococcus infernus 
C95/98S 1-65 
His tag, non-his tag petDuet, Amp resistance non-his; 
pet28b, Kan resistance for his 
Methanocaldococcus infernus 
C95/98S 1-73 
His tag, non-his tag petDuet, Amp resistance non-his; 
pet28b, Kan resistance for his 
Methanocaldococcus infernus 
Y517A 
His tag, non-his tag petDuet, Amp resistance non-his; 
pet28b, Kan resistance for his 
Methanocaldococcus infernus 
Y518A 
His tag, non-his tag petDuet, Amp resistance non-his; 
pet28b, Kan resistance for his 
Methanocaldococcus infernus 
C95S 
His tag, non-his tag petDuet, Amp resistance non-his; 
pet28b, Kan resistance for his 
Methanocaldococcus jannaschii 
C96/101/104S 
His tag, non-his tag petDuet, Amp resistance for his and 
non-his 
Methanocaldococcus vulcanius 
M7 C97/100S 
His tag, non-his tag petDuet, Amp resistance for his and 
non-his 
Methanotorris formicicus, 
C98/101S 
His tag, non-his tag petDuet, Amp resistance for his and 
non-his 
Methanocorpusculum 
labreanum, C88/91S 
His tag, non-his tag petDuet, Amp resistance for his and 
non-his 
Table 4.1. Elp3 constructs. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1. (cont.) 
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Methanocaldococcus infernus 
5’ Min-XbaI-ELP3-Non-his-tag 
GCGTAC TCTAGA AATAATTTTGTTTAACTTTAAGAAGGAGATATACC 
ATGAAAGAGAAGCTAATGAGATG 
3’ Min-BamHI-ELP3-Non-his-tag 
GCGAT GGATCC TTAAAGCTCTTTCCCCATATAAG 
5’ Min-NcoI-ELP3-His 
GCGTAC CCATGGGC CATCATCATCATCATCAC GGCGGC 
AAAGAGAAGCTAATGAGATGTAT 
3’ Min-NheI-ELP3-His 
GCGAT GCTAGC TTAAAGCTCTTTCCCCATATAAG 
Quikchange primers for MinElp3 C95/98S: 
MI-C95/98S-Fwd 
GTCCACATGGTAAATCTATCTTTTCCCCTGGAGGTTTAGATAG 
MI-C95/98S-Rev 
CTATCTAAACCTCCAGGGGAAAAGATAGATTTACCATGTGGAC 
Quikchange primers for MinElp3 Y517A: 
MI-Y517A-Fwd 
GGAATAGGGGTTAGGGAAGCTTACAGAAAGTTGGGGTATAAAAGAG 
MI-Y517A-Rev 
CTCTTTTATACCCCAACTTTCTGTAAGCTTCCCTAACCCCTATTCC 
Table 4.2. Primers for frequently used Elp3 clones. 
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CHAPTER 5: BIOCHEMICAL STUDIES ON A RADICAL REACTION CATALYZED 
BY VIPERIN 
 
5.1. Introduction 
  
Although the mode of action of viperin has remained elusive, there have been several 
important studies which have enabled further investigation into its molecular mechanism: (i) The 
antiviral activity of viperin occurs at the late stage of viral infection (87,104), (ii) A yeast two-
hybrid system revealed that viperin interacts with and inhibits farnesyl diphosphate synthase 
(FPPS) (104) and (iii) The motifs required for coordination with [4Fe-4S] and SAM are essential 
for antiviral activity (87,99). 
A BLASTp search of human viperin was performed against the PDB database. The top hit 
was the structure of MoaA (76), which shares modest sequence identities (23%) with human 
viperin only in the radical SAM domain. MoaA is involved in the first step of Molybdenum 
cofactor synthesis using GTP. Structural analysis of the MoaA-GTP complex, along with the 
aligned sequences of MoaA and human viperin, revealed that several MoaA residues responsible 
for binding of the triphosphate motif of GTP are conserved in viperin (Fig. 5.1). This indicates that 
the substrate(s) of viperin might contain a phosphate(s) motif. Thus, instead of FPPS, one of the 
pyrophosphate compounds within the mevalonate pathway could be the substrate(s) of viperin.  
To understand human viperin and its relationship with viperin homologs from other 
organisms, a Sequence Similarity Network of viperin was constructed using human viperin as the 
seed for BLASTp (Fig 5.2A). While a majority of viperin is found in eukarya (Fig. 5.2A, magenta 
nodes), Viperin homologs are also found in 12 archaea (Fig. 5.2A, green nodes) and ~60 bacteria 
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(Fig. 5.2A, blue nodes). Within eukarya, viperin are primarily from the kingdoms Animalia and 
Fungi (117 and 74, respectively). Viperin is highly conserved within eukarya, demonstrated by the 
tight cluster within the Sequence Similarity Network. For instance, viperin from human and 
Trichoderma virens (fungus) share 55% sequence identities in the radical SAM and C-terminal 
domains. Moreover, human and mouse viperin share 92% sequence identities. Conversely, 
prokaryotic viperin (bacteria in particular) are more diverse (Fig. 5.2A, green and blue nodes).  
The mevalonate pathway is involved in the biosynthesis of isoprenoids, which play a 
critical role in diverse cellular functions in humans including cholesterol biosynthesis and protein 
prenylation (133). The pathway begins with acetyl-CoA and results in the production of several 
isoprenoids, the first being a 5-carbon building block called isopentenyl pyrophosphate (IPP) (Fig. 
5.3).  IPP inter-converts to dimethylallyl pyrophosphate (DMAPP). DMAPP reacts with 
isopentenyl pyrophosphate to form geranyl pyrophosphate. Condensation of 
geranyl pyrophosphate with another isopentenyl pyrophosphate yields farnesyl pyrophosphate. 
Condensation of isopentenyl pyrophosphate with farnesyl pyrophosphate yields geranylgeranyl 
pyrophosphate.  
Condensation of two molecules of FPP, followed by reduction by NADH, results in the 
production of squalene. Next, squalene undergoes a two-step cyclization to yield lanosterol, which 
(after 19 reactions) is converted to cholesterol. These 19 reaction steps are catalyzed by enzymes 
localized either to the ER or to the peroxisomes (134). Prenylation is performed by 
farnesyltransferase and geranylgeranyl transferases. This involves the covalent attachment of 
hydrophobic molecules (either the C-15 isoprene farnesyl or the C-20 isoprene geranylgeranyl 
groups) to the C-terminal end of some proteins to promote attachment of these proteins to internal 
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cell membranes (135). This chapter discusses our studies demonstrating that IPP (one of the 
substrates of FPPS), and not FPPS, is the substrate of viperin. 
 
5.2. Materials and Methods 
 
Cloning, expression and purification of viperin  
In order to clone his-tagged versions of viperin, synthetic viperin genes from various 
organisms were codon optimized for Escherichia coli and ordered from IDT. In order to clone the 
non-his tagged versions of the same viperin genes, primers were ordered and the synthetic genes 
were used as templates (Table 5.1). That is, the required fragment was amplified by PCR and 
inserted into the petDuet-1 vector (Novagen). The plasmid was transformed into the Escherichia 
coli expression strain BL21 (DE3) (Invitrogen). A single colony was used to inoculate a starter 
culture, which was grown overnight at 37 °C. This was used to inoculate 1 liter of lysogeny broth 
containing 100 μg/ml ampicillin. Cells were grown at 37 °C to A600nm of approximately 0.4 and 
cooled to 18 °C. Expression was induced with 0.5 mM isopropylthiogalactoside (IPTG). Cells 
were grown overnight at 18 °C and collected by centrifugation.  
All versions (full-length, truncations, mutations) of the recombinant his-tagged TviViperin 
was purified to homogeneity using the AKTA FPLC (with degassed buffers) using the Ni column 
(Ni A: 20 mM Tris-HCl pH 8.0, 100 mM NaCl, Ni B: 20 mM Tris-HCl pH 8.0, 100 mM NaCl, 
500 mM Imidazole). Fractions were pooled and diluted using DEAE A buffer (20 mM Tris-HCl 
pH 8.0, 10 mM NaCl, 2% glycerol). Next, the protein was purified using the MonoQ column using 
DEAE A and DEAE B buffer (20 mM Tris-HCl pH 8.0, 1 M NaCl, 2% glycerol). Next, the selected 
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fractions were purified using the Superdex 75 size-exclusion column and GF buffer (10 mM 
HEPES pH 7.0, 200 mM NaCl, 2% glycerol).  
All versions of the recombinant non-his tagged TviViperin were purified using the SP 
column with SP A (20 mM HEPES pH 6.5, 10 mM NaCl, 2% glycerol) and SP B (20 mM HEPES 
pH 6.5, 1 mM NaCl, 2% glycerol) buffers. Fractions were pooled and purified using the Mono Q 
column using DEAE A and B buffers. Lastly, fractions were purified using the Superdex 75 size-
exclusion column with GF buffer.  
The recombinant his-tagged MliViperin was purified similarly to his-tagged TviViperin, 
paying close attention to precipitation. The recombinant non-his tagged VvuViperin was purified 
using the DEAE column (with DEAE A and B buffers). Next, it was purified using the Heparin 
(using DEAE A and B buffers) and Superdex 75 size-exclusion column with GF buffer. 
 
In vitro reconstitution of the viperin-catalyzed reaction 
The cell pellet was moved inside the chamber and allowed to thaw for about 20 minutes. 
Ni A buffer (20 mM Tris-HCl pH 8.0, 100 mM NaCl) was added to the pellet. It was then vortexed, 
allowed to thaw completely and vortexed again. The re-suspended cells were moved out to be 
quickly lysed with a French press. It was then moved inside on a bucket of ice. The cell lysis was 
allowed to equilibrate inside the chamber for 15 minutes on ice. It was then spun in eppendorf 
tubes at 14,000 RPM for 15 minutes. The supernatant was transferred to a new tube and iced for 5 
minutes. It was then spun again for 15 minutes at 14,000 RPM (Note: As MliViperin is unstable, 
it was spun for 3 periods of 10 minutes with icing in-between). The supernatant was then filtered 
using 0.45 uM filters.  
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The following elution buffers were prepared by mixing Ni A and Ni B (Tris-HCl pH 8.0, 
100mM NaCl, 500mM Imidazole) buffers: 10 mM Imidazole (40 uL Ni B + 1960 uL Ni A), 20 
mM Imidazole (80 uL Ni B + 1920 uL Ni A), 40 mM Imidazole (160 uL Ni B + 1840 uL Ni A), 
80 mM Imidazole (320 uL Ni B + 1680 uL Ni A), 130 mM Imidazole (520 uL Ni B + 1480 uL Ni 
A) and 150 mM Imidazole (600 uL Ni B + 1400 uL Ni A). 
The Ni column was equilibrated with 10 mLs of Ni A buffer. The supernatant was injected 
slowly and the flow-through was collected. The column was washed with 5 mL NiA buffer. Next, 
the protein was eluted using the Ni A + Ni B mixtures. The protein eluted at 80 mM and 130 mM 
and has a reddish-brown colour; it was stored on ice. 
10 kDa filters were equilibrated with reaction buffer (100 mM NaCl, 50 mM Tris pH 7.5, 
5% glycerol) or with GF buffer (10 mM HEPES pH 7.0, 200 mM NaCl and 2% glycerol) if the 
protein was going to be crystallized.  The protein was concentrated by spinning at 8000 RPM for 
10 minutes. It was then iced and spun again if necessary. The protein was then equilibrated twice 
with cold Reaction buffer or GF buffer. 2 uL of the concentrated protein was moved into to an 
eppendorf tube to be taken outside to measure the concentration.  
To prepare for the reaction, dry Na2S2O4 (between 10 and 17 mg) and vacuum dried and 
purified SAM and IPP were moved into the chamber. They were allowed to sit inside the chamber 
for ~30 minutes before usage. The dry chemicals were re-suspended in appropriate volumes of 
Reaction Buffer. To start the reaction, reagents were added in the following order: Reaction Buffer, 
SAM, IPP, enzyme (incubate for 10 minutes) and Na2S2O4. The reaction was incubated at room 
temperature for 1 hour. The reaction was stopped by adding 8 M guanidine hydrochloride. It was 
removed from the chamber, frozen with liquid nitrogen and stored at in the -80 °C freezer.  
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5.3. Results and Discussion 
 
Reconstitution of the TviViperin-catalyzed radical reaction in vitro 
12 viperin genes, equally distributed between bacteria, archaea and eukarya, were selected 
to aid in biochemical and structural characterization of viperin. Synthetic genes were ordered from 
IDT following codon-optimization in Escherichia coli. Of the 12 viperin genes, only viperin from 
Trichoderma virens (TviViperin) was soluble and viperin from Methanofollis liminatans was 
partially soluble. In vitro reaction was first performed using TviViperin. Viperin was purified 
inside an anaerobic chamber without further reconstitution of [4Fe-4S]. The standard reaction was 
performed using 200 uM SAM, 200 uM substrate, 100 uM TviViperin and 1 mM Na2S2O4 
(reducing agent) for 1 hr at room temperature. The reaction was stopped with the addition of 8 M 
Guanidine hydrochloride. The sample was filtered and the flow-through of the sample was 
analyzed by HPLC and LC-MS (Fig 5.4). 
 In the absence of the reducing agent, which serves as the electron donor to initiate the 
radical based reaction, only SAM and its decomposed derivative, methylthioadenosine (MTA) 
(Fig. 5.4A, panel 1) were observed. Addition of Na2S2O4, resulted in the formation of 5’-dA•, 
which was quenched to form 5’-HSO2A and 5’-dA in the absence of the substrate (Fig. 5.4A, panel 
2). Addition of DMAPP produced similar results (Fig. 5.4A, panel 3), indicating that DMAPP is 
not a substrate. When IPP was used as the substrate, a new major product (Fig. 5.4A, panel 4, 
asterisk) was formed in addition to 5’-HSO2A and 5’-dA (minor products). High resolution 
LC/ESI-MS indicated that the mass of this new product equals the mass of 5’-dA + IPP + 1 Dalton. 
This is consistent with the radical addition of 5’-dA• to the double bond in IPP, followed by 
abstraction of a hydrogen atom from the surrounding solvent (Fig. 5.7).  
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 The new product has been tentatively named adenylated isopentyl pyrophosphate (AIPP). 
This experiment demonstrates the selectivity of the reaction because DMAPP and IPP share the 
same chemical structure except for the location of the double bond. Reactions with GPP, FPP, 
GGPP as substrates yielded similar results. The consumption of SAM in the reaction with IPP is 
lower than in the reactions without a substrate and with DMAPP. This may be a result of product 
inhibition by AIPP and the experiments in the next section further explore this observation.   
 
Product inhibition of the TviViperin-catalyzed reaction 
 To further understand the slow reaction with IPP, a time-course of the TviViperin with IPP 
and DMAPP was performed (Fig. 5.5). For the reactions with DMAPP as substrate, production of 
5’-HSO2A and 5’-dA increased over time, concurrent with the reduction in SAM (Fig. 5.5, green 
and blue curves). After a 2 hour reaction period, all SAM was converted to either 5’-HSO2A or 5’-
dA. The ratio of SAM to enzyme was 2:1, indicating that the reaction proceeded with turnover. 
When IPP was used as the substrate, AIPP was produced rapidly initially and levelled off between 
30 minutes and 2 hours (Fig. 5.5, magenta curves). This indicates that AIPP may inhibit subsequent 
enzymatic reactions. Based on the percentage of SAM converted to AIPP, 5’-HSO2A and 5’-dA, 
it is estimated that 40% of TviViperin was enzymatically active.   
  
Enzymatic reactions carried out by recombinant MliViperin and HsaViperin-∆50 
The reaction were also performed with MliViperin (Fig. 5.6A, panel 1). Similar to 
TviViperin, IPP was the substrate, while DMAPP, GPP, FPP and GGPP were not. Product 
inhibition was also observed in the reaction catalyzed by MliViperin. Unlike TviViperin, however, 
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MliViperin appeared to promote dephosphorylation of AIPP, resulting in the formation of AIP (Fig 
5.6A, panel 1).  
 The reaction was also performed with human viperin lacking the first 50 amino acids at the 
N-terminus (HsaViperin-∆50). This construct was previously shown to express partially soluble 
protein in Escherichia coli (136). A small peak corresponding to AIPP was observed (Fig. 5.6A, 
panel 2) and its identity was confirmed as AIPP by high resolution LC/ESI-MS (Fig. 5.6B). 
HsaViperin-∆50 was less active than MliViperin and TviViperin.  
 To compare the efficiency of production of AIPP, an arbitrary term, Reaction Yield, will 
be used. The Reaction Yield for a specific reaction will be defined as the percentage of 5’-dA• that 
is converted to the product AIPP. The Reaction Yield of the reaction catalyzed by TviViperin is 
68%, the one catalyzed by MliViperin is 70%. The Reaction Yield of HsaViperin-∆50 is 15%. 
This may be because MliViperin and TviViperin lack the N-terminal ER-association domain, and 
may be more capable of performing the reaction in solution. In contrast, HsaViperin may require 
association with the ER or lipid droplets to perform the reaction optimally. 
 Based on these studies, it may be possible that viperin exerts its antiviral activity by 
catalyzing a unique reaction with IPP, which is a key intermediate of the mevalonate pathway. 
Viperin may deplete the IPP pool, which may in turn affect several downstream processes such as 
cholesterol biosynthesis and protein prenylation. Also, the product of the reaction, AIPP, may be 
a new signaling molecule or inhibitor with antiviral activity. Future studies will focus on 
understanding the molecular mechanism of the viperin-catalyzed reaction in vivo. As viperin acts 
on the same biosynthetic pathway as Statins, a class of cholesterol-lowering drugs, it may be 
explored for alternative therapeutics.   
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 Viperin has also been shown to inhibit (+) strand and not (-) strand RNA synthesis of tick-
borne encephalitis virus (TBEV) in human cells. AIPP may be an inhibitor of the methyltransferase 
(MTase) domain of nonstructural protein 5 (NS5) of flaviviruses (Fig. 5.8), which is responsible 
for (+) viral RNA genome capping during viral replication. This is further supported by the fact 
that the viperin-catalyzed reaction and viral RNA replication of flaviviruses occur on the 
cytoplasmic face of the endoplasmic reticulum. Thus, AIPP may be explored for treatment of 
diseases caused by flaviviruses.  
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5.4. Figures 
 
Fig. 5.1. Conservation between human viperin and MoaA. Blastp of human viperin (HsaV) 
against the PDB database using standard NCBI settings revealed the structure of MoaA as the 
only positive hit. Seven of the eight MoaA residues involved in recognition of the triphosphate 
motif of GTP are highlighted in red; three of them are conserved in human viperin. 
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Fig. 5.2.  Distribution and domain structure of viperin. A. SSN of viperin based on BLASTp search 
of human viperin. Three viperin employed in our study are marked with arrows. Hsa, Humans; 
Tvi, Trichoderma virens; Mli, Methanofollis liminatans. B. Domain structures of three 
recombinant viperin under study. The domains were defined, aided by the crystal structure of 
TviViperin. Human viperin possesses a N-terminal domain for ER association (orange), which is 
absent in TviViperin and MliViperin.  
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Fig. 5.3. Schematic overview of the mevalonate pathway. IPP is the essential building block 
responsible for all downstream isoprenoid biosynthesis. IPP is synthesized from mevalonate. The 
synthesis of mevalonate is inhibited by the class of cholesterol lowering drugs, Statins (red). A 
new branch illustrating the conversion of IPP to AIPP is highlighted in red.  
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Fig. 5.4. In vitro reconstitution of TviViperin activity. A. RP-HPLC chromatograms of the 
reactions. Panel 1, no Na2S2O4; panel 2, no substrate; panel 3, DMAPP as substrate; panel 4, IPP 
as substrate. MTA, methylthioadenosine. B. High resolution LC/ESI-MS analysis of 5’-HSO2A in 
the reaction sample shown in panel 3. C. High resolution LC/ESI-MS analysis of the new product 
formed in the reaction sample shown in panel 4. CM, calculated mass. 
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Fig. 5.5. Kinetics of viperin-catalyzed reaction. The concentration of SAM and products are 
plotted against the reaction time for the reactions using DMAPP and IPP as substrates.  
 
 
  
Fig. 5.6. In vitro reconstitution of MliViperin and HsaViperin activities. A. RP-HPLC 
chromatograms of the reactions catalyzed by MliViperin (panel 1) and HsaViperin-ΔN50 (panel 
2) using IPP as substrate. B. High resolution LC/ESI-MS analysis of the product marked with an 
asterisk in panel 2. 
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Fig. 5.7. Proposed mechanism of the viperin-catalyzed reaction.  
 
 
Fig. 5.8. Docking AIPP into the crystal structure of MTase domain of NS5 from dengue virus. A-
C, MTase domain of the crystal structure of NS5-SAH-RNA ternary complex (PDB accession 
code: 5DTO) was divided into three displays, showing A. empty, B. SAH bound and C. RNA 
bound reaction center. D. The same view with docked AIPP. AIPP might inhibit MTase of NS5 
with its 5’-dA motif recognized by the SAM-binding pocket, and its negatively charged 
pyrophosphate motif recognized by the RNA-binding groove, which is very positively charged. 
A B
CD
 97 
 
CHAPTER 6: MOLECULAR BASIS OF A RADICAL REACTION CATALYZED BY 
VIPERIN 
 
6.1. Introduction 
 
Human viperin is composed of 361 amino acids and is approximately 42 kDa. It consists 
of a variable N-terminal domain, a conserved central domain containing the radical SAM motif 
CX3CX2C and a highly conserved C-terminal domain (Fig 5.1B). The N-terminal domain has been 
known to allow viperin to associate with the cytosolic phase of the endoplasmic reticulum (ER) 
and lipid droplets (96,97). Viperin has been shown to bind [4Fe-4S] and catalyze the reductive 
cleavage of SAM (98). Furthermore, the [4Fe-4S] binding motif is essential for its antiviral 
activities in hepatitis C virus (HCV) and HCMV (91,99). The aromatic amino acid at the C 
terminus of viperin is also required for its antiviral activity against HCV (99). Therefore, this 
residue may be involved in protein-protein interactions and/or substrate recognition (100).  
 
6.2. Materials and Methods 
 
Cloning, expression and purification of viperin 
Described in Chapter 5.2. 
  
Crystallization, data collection and structure determination 
Crystals of the His-tagged TviViperin-∆1-10 were grown by the hanging-drop vapor 
diffusion method at 4 °C. The purified protein (~7 mg/mL) was mixed with a reservoir solution 
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containing 1.6 – 1.8 M ammonium sulfate and100 mM sodium citrate pH 5.5 – 5.7. Crystals 
appeared after 3-7 days. Crystals of the his-tagged TviViperin-∆1-10 were also obtained from 1.5-
1.6 M sodium malonate pH 6.8 at 4 °C. 
Crystals of the His-tagged full length TviViperin were obtained from 1.5-1.8 M sodium 
malonate pH 7.1-7.8 at 4 °C; however, these did not diffract X-rays well. Crystals of non-his 
tagged version of TviViperin-∆N∆C were obtained from 1.7-1.8 M ammonium sulfate, 100 mM 
sodium citrate pH 5.7 – 5.9, which diffracted to 3 Å. Small crystals were obtained from VvuViperin 
which was purified using the AKTA FPLC (concentrated to 4-5 mg/ml) and crystallized at room 
temperature inside the anaerobic chamber. Crystals were obtained from 2 M ammonium sulfate 
and 100 mM sodium citrate pH 5.5. Purification schemes are described in Chapter 5.2.  
Crystals were soaked briefly in a cryo-protection solution containing all of the components 
of the reservoir solution supplemented with glycerol, and the cryo-protected crystals were mounted 
in a nylon loop and flash-frozen in liquid nitrogen. Data was collected at the Advanced Photon 
Source (APS) and processed using the HKL2000 program. Phase was determined based on a 
SeMet SAD data using the Phenix program. A partial model was automatically built using Phenix. 
The remaining model was manually built using the Coot program. Refinement was done using 
Phenix.  
 
Crystallization for determination of [4Fe-4S] 
Viperin was purified using the technique for purification of protein inside the chamber as 
described in Chapter 5.2. The protein in fraction 4 (eluted with 80 mM imidazole) was 
concentrated using a 10K centricon. Buffer exchange was performed twice with iced Gel filtration 
buffer (10 mM HEPES pH 7.0, 200 mM NaCl, 2% NaCl). The protein was concentrated to 7-8 
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mg/ml. Sitting drop trays were used to perform crystallization. 2 uL of protein was added to 2 uL 
of well solution. Plates were sealed with tape and placed inside the cooler (~7 °C). Crystals were 
obtained from 0.7-0.8 M ammonium sulfate, pH 5.7-5.8.  
TviViperin was also crystallized following chemical reconstitution of [4Fe-4S]. 1 L 
TviViperin was purified inside the anaerobic chamber and the protein in fraction 4 (eluted with 80 
mM imidazole) was chemically reconstituted using the technique described in Chapter 3.2. The 
following day, the reconstituted protein was desalted using a NAP-10 column, buffer exchanged 
with iced Gel Filtration buffer and concentrated to ~ 8mg/ml. 2 uL of protein was added to 2 uL 
of well solution in sitting drop trays. Crystals were obtained from 0.5-0.9 M ammonium sulfate 
and 100 mM sodium citrate buffer pH 5.8 in the cooler inside the anaerobic chamber (~7 °C). 
 
6.3. Results and Discussion 
 
Crystal structure of TviViperin 
 The His-tagged version TviViperin-∆1-10 (deletion of first ten amino acids) was 
crystallized under aerobic conditions and the structure was solved to 2.8 Å. Twelve copies of 
viperin were found in an asymmetric unit forming a sphere-shaped structure (Fig. 6.1). This 
structure is unlikely to be biologically relevant as viperin was shown to be a monomer in solution 
via chromatography. The structure shows that viperin has the conserved SAM motif (Fig. 6.2, 
green), which is fused to the C-terminal domain which is unique to viperin (Fig. 6.2, purple). The 
C-terminal domain adds additional structural elements to both ends of the radical SAM motif, 
linked by a 9 amino acids cross-over loop. The C-terminus folds back to the center of the C-
terminal domain.  
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Docking IPP, 5’-dA•, Met, and [4Fe-4S] into the structure of TviViperin 
A Dali structural search revealed the structure of MoaA (76) as the top score (Fig. 6.3). 
The crystal structure of MoaA contains [4Fe-4S], 5’-dA• (with disordered C5’), Met, and GTP. To 
dock IPP into the central channel of viperin (Fig. 6.4B), the triphosphate motif of GTP from the 
aligned MoaA structure was used as the guide. Specifically, C1, Pa, and Pb of IPP was 
superimposed on Pα, Pβ and Pγ of GTP, respectively, followed by manual adjustments of the C2-
5 motif of IPP to fit the central channel of viperin. Following manual docking of IPP, 5’-dA•, Met, 
and [4Fe-4S] from the aligned MoaA structure were added directly without further positional 
adjustments. IPP fits the channel snugly (Fig. 6.4B), and 5’-dA•, Met, and [4Fe-4S] also appear to 
fit well near the entrance of the channel (Fig. 6.4C, D). The relative position of IPP and 5’-dA• 
indicates a likely radical addition of 5’-dA• to the terminal C-C double bond in IPP (Fig. 6.4E, 
arrow). Also, even if DMAPP is able to enter the central channel and position itself similarly to 
IPP, the radical addition will not occur because the central C-C double bond (between C2 and C3) 
in DMAPP is too far for 5’-dA• to reach. Finally, the models predict that GPP, FPP, and GGPP 
are too long to be the substrates of viperin. 
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6.4. Figures and Tables 
 
 
 
Fig. 6.1. Structure of viperin. 12 copies of viperin form an asymmetric unit.  
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Fig. 6.2. Cartoon and surface model of the viperin monomer from A. IPP side and B. SAM side. 
Structures are colored the same as in Fig. 5.1B. The surface is colored for electrostatic potential: 
blue for basic, white for neutral, and red for acidic residues. 
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Fig. 6.3. Comparison of MoaA ([4Fe-4S], 5’-dA• (with disordered C5’), Met, and GTP) and 
TviViperin. MoaA is coloured cyan (radical SAM domain) and yellow (C-terminal domain). A. 
[4Fe-4S], 5’-dA• and Met shown in stick form. B. GTP shown in stick form.  
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Fig. 6.4. Snapshots of docking models. A-D. Close-up views of the central channel in viperin 
(viewed from SAM side) with A. the channel empty, B. docked with IPP, C. IPP + 5’-dA•, and D. 
IPP + 5’-dA• + Met + [4Fe-4S]. E. Side view of the docked IPP and 5’-dA•. An arrow denotes 
radical addition of 5’-dA• to the C-C double bond in IPP. 
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Fig. 6.5. Alignment of viperin from fungi, vertebrates and archaea. Strictly conserved residues are 
shown in magenta, identical residues in yellow and similar residues in cyan. The secondary 
structure above the alignment corresponds to TviViperin.  
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Table 6.1. 
Viperin clones: 
Organism Versions cloned Solubility notes 
Vibrio Vulnificus (Vvu) His tag (H) Low expression 
  Non-his tag (NH) High expression, heavy precipitation 
Sulfurimonas gotlandica  H (did not clone)  
  NH Insoluble 
Marine DNA H Very low expression 
  NH Very low expression 
Methanofollis liminatans H High expression, precipitation 
  NH Low expression 
Trichoderma virens (Tvi) H High expression, stable until 7 mg/ml 
  NH High expression, stable 
Bipolaris Maydis H Low expression, very heavy precipitation 
  NH   
Photobacterium Profundum H High expression, insoluble 
  NH   
Haemophilus haemolyticus  H Low expression, mostly insoluble 
  NH   
Hypocrea virens H Low expression, mostly insoluble 
  NH   
Methanoplanus limicola H High expression, insoluble 
  NH High expression, insoluble 
Trichoderma atroviride H High expression, insoluble 
  NH   
Methanoculleus bourgensis H  Insoluble 
  NH  Insoluble 
Homo sapiens H Low expression 
 NH  
 
Viperin mutant clones: 
Viperin mutant clones Versions cloned Solubility notes 
Tvi C-terminal truncation N294Stop H High expression, stable 
  NH   
Tvi N-terminal-truncation ∆1-10 H High expression, stable 
  NH   
Tvi ∆N∆C, ∆1-10 + ∆294-308 H High expression, stable 
  NH High expression, stable 
Tvi  ∆N1-10 + G290Stop H High expression, stable 
Tvi ∆N1-10 + I291Stop H High expression, stable 
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Tvi ∆N1-10 + G289Y + G290Stop H High expression, stable 
Tvi ∆N1-10 + G289Y + I291Stop H High expression, stable 
Tvi C35/38S H High expression, insoluble 
  NH   
Vvu C26/29S H High expression, insoluble 
  NH   
Table 6.1. Viperin constructs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.1. (cont.) 
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Table 6.2. 
Vibrio vulnificus 
gBlock for cloning His-tag version: 
>Vibrio vulnificus-BamHI-EcoRI-His 
GCGATGGATCCGATGACTACTG CACAATCTCG CAAAACGAAA GAACTGGTTA 
TCAATTGGCA TATGACTGAA GTATGCAATT ACAGTTGCAA GTATTGTTTT 
GCTAAGTGGG GCCGCCCAAA GGAACTGCAT CGTTCCGAGC AGGCCATTGA 
TAATCTCCTG GATAAACTGG CTGATTATTT TATCAAAGGC ACCCCGGTGC 
TGAAAGAAAA GCTGGGTTAT GAATCCGTGC GTCTTAACTT TGCCGGCGGT 
GAGCCAATGA TGTTAGGAAA TACTTTTGTG ACCGCGCTGG TTCTGGCCAA 
ACAAAAAGGC TTCAAGACGT CGACCATTAC TAACGGCCAC TATTTGATCC 
ACGGCAAATC CCCGCTCCCA AAAGACACTC TTGATATGAT TGGCATTTCT 
TTCGACTCTC AGTATCTTAG TACTCGTATG AAAATTGGCC GGAACGACCG 
TAAAGGTAAC TCTTTTGGCG TCAACGATCT GACCCATGCA CTGGCCCGTC 
TGACCCAGTC ACAAACCGGC ATCAAGACTA AAATTAATAC GGTAATTAAC 
TCATTAAACT GGGAAGAAGA TTTCACCAAT CTGATTAGCA GCCTGAACCC 
GTACAAATGG AAAGTTCTGC AAGTGATGCC ATACGGTGAC AACGAGCTGT 
TAATCAGTAA AGAACAGTTT GACAACTTCG TCCATCGTCA TAGCGGGTTG 
GGCTTACCGA TCTATTTTGA GAGCAATAGC ACGATGACGG AGAGCTACTT 
AATGATCAGT CCGGAAGGTT GTTTCTATCA GAACACCGCC AACAAGAGTG 
GATATAAATA TAGCGAATGT ATTAACAGTT GCGGTGTGGA AAAAGCTTTA 
TCCCAGATCG AATTTAACCC AATCACCTTC GCCAGCCGTT ATAAAAAAAC 
GAATATCGAC ATCGTTGACG TTTCTTGAGAATTCATCGC 
Primers for cloning Non-His-tag version: 
5’-Vv-XbaI-NH 
GCGTAC TCTAGA AATAATTTTGTTTAACTTTAAGAAGGAGATATACC 
ATGACTACTGCACAATCTCGC 
3’-Vv-EcoRI 
GCGAG GAATTC TCAAGAAACGTCAACGATGTC 
Methanofollis liminatans 
gBlock for cloning His-tag version: 
>Methanofollis liminatans-His-BamHI-EcoRI 
GCGATGGATCCGATGCCCACGC CATCTACCAT CCGTAGCGTA AATTGGCACC 
TGATCTCTGC TTGTAACTAT AGTTGCCGTT TCTGCTTTGC CCGTAATCTG 
GGTGAAACCC CCGTGTCATT CAGCGAAGGG TGTCGCATTT TAACGCGTCT 
GGTCGGCGCC GGTATGGAAA AAATTAACTT CGCGGGAGGG GAGCCGCTGC 
TGCACCCGCA GCTGTTTGAG TACTGTCGCG TGGCGCACGA CCTCGGTATG 
ACCGTCAGTA TTACCACGAA CGGGAGTCGC CTGACACCGG AGCTGGTGCG 
CACACATCGT GGCTACATCG ATTGGATTGC TCTGTCTGTC GACTCGGCAT 
CTGAGGAGAC CGAAGCCCGT CTGGGGCGCG GAGATGGTCA GCACGTGGGA 
CATTGCATTC GTCTTAGCGA TGCGATCCGC GAGACAGGTA TCCGCCTTAA 
AATCAATACG ACTGTGACTG CCCTGTCACG CGACGAGGAT ATGACGGGGT 
TCGTCCGTCG CACTGATCCA GACCGCTGGA AAGTGCTGCA GATGCTGCAT 
ATCCGTGGTG AAAATGACGG CGCAGTAGCA GATCTGTCGG TAACGGATGC 
TGAATTTCGC GCATTTGCAG ATCGCCATGC GGGAGTGATT CTGCGTGGAG 
GTGTGCTGCC GGTTTTTGAA TCCTCGGCGA TGATTGAAGG CTCCTACTTT 
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ATGGTTACTC CGGGTGGACG CGTCAAAACC GATACCGGCC GTGTGATTCG 
TAAATACAGC CTTGATGAAG TGCTCGGCTC GGGCGTTTTC GCGTATGTTG 
ATGAGGGACA ATACCTTCGT CGCGGTGGCG TTTATGCTTG 
GTGAGAATTCATCGC 
Primers for cloning Non-His-tag version: 
5’-ML-NH-XbaI 
GCGTACTCT AGA AAT AATTTT GTTTAA CTTTAA GAA GGA GAT ATA CCA TGC 
CCA CGC CAT CTA CCA  
3’-ML-NH-NotI 
GCG AGG CGG CCG CTC ACC AAG CAT AAA CGC CAC  
Trichoderma virens 
gBlock for cloning His-tag version: 
>Trichoderma virens-His 
GCGATGGATC CGATGAAAGA TAATCAAGAA GCTGCAGCAT TTGGCGGGCG 
TGTTCGGACA GGACAGGTTC CGGTCTCGGT GAACTACCAT TTTAGCCGCA 
AATGTAATAA AGAATGCTTA TTTTGTTTTC ATACAGCCAC CACGAGTCAT 
GTTGAAAAAC CGGAAAATGC GAAACGCGGG CTTACGCTGC TGAAACAGGC 
GGGTATGAAA AAGATTAATT TTGCGGGTGG CGAGCCGTTC CTGTATCCGA 
AGTTCTTGGG AGAAATGATT GATTTTTGTA AGGAGACTCT GCAGCTTGAA 
AGCGTATCCA TCGTCACCAA CGGTAGCCTT GTTAAGGAAC AGTTTCTTCA 
AAAACATGGA CGCAATATCG ATATCCTTGC GGTTAGTTGT GATTCGTTTA 
ATGAAGCCAC AAACATTAAA ATTGGTCGTG GTTCCGGTGA TAATGTGCAG 
AAGCTGTATG AAATTGGCAG TTGGTGCCAG AAATATGATA TTAAGTTTAA 
ATTAAACACC GTGGTTAATA AGTTCAATCA CCTGGAGGAC ATGAACGATC 
ACCTCAATGC GCTGCAGCCT TTTCGTTGGA AATGTTTCCA GGTTCTCATT 
GTCACAGGTG AGAATGATTC GGATAAAACG CTGCGGAATG CGCATAGCCT 
TACAATTTCG GATGATGAGT TCGATCGTTT TTGCGAGCGG CACTCCTCAC 
AGACCTGCTT AGTTCCTGAA CCGAACCGTT TGATGGCGAA AAGCTATTTA 
ATCTTGGATG AGTACATGCG TTTCTTGGAT CGTAACGGGC AACAGCCATC 
GAAATCTATT CTGGAAGTCG GTGTCCAGCA AGCGCTCCAA GCCGTTTTTT 
GGGATGAAGA AGCCTTCGTA GAACGTGGTG GTATCTACGA TTGGAATAAA 
TCTTCCTGTT CGAGCGATTC AAAAGATCTG GAATGGTGAG CGGCCGCATC GC 
Primers for cloning Non-His-tag version: 
5’-Tv-XbaI-NH 
GCGTACTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGAAAGA
TAATCAAGAAGCTGC 
3’-Tv-NotI-NH 
GCGAGGCGGCCGCTCACCATTCCAGATCTTTTGAAT 
Primers for Tv His-tag ∆1-10: 
5’-Tv-NH-Ntrunc-NcoI 
GCGTAC CCATGG GCGGGCGTGTTCGGACAG 
5’-Tv-H-Ntrunc-BamHI 
GCGAT GGATCCG ATGGGCGGGCGTGTTCGGAC 
Quickchange primers for C-terminal truncation (N294 after W to STOP): 
Tv-NtoStop-Fwd 
GGTGGTATCTACGATTGGTAAAAATCTTCCTGTTCGAGCG 
Table 6.2. (cont.) 
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Tv-NtoStop-Rev 
CGCTCGAACAGGAAGATTTTTACCAATCGTAGATACCACC 
Tv∆N∆C (∆1-10 + ∆294-308) 
His-tag and Non-His tag version cloned using Tv ∆1-10 plasmid and primers for Tv ∆C 
Quickchange primers for Tv G290Stop + ∆1-10 (used Tv H ∆1-10 as template)  
G290Stop-Fwd 
GAAGCCTTCGTAGAACGTGGTTGAATCTACGATTGGAATAAATC 
G290Stop-Rev 
GATTTATTCCAATCGTAGATTCAACCACGTTCTACGAAGGCTTC 
I291Stop + ∆1-10 
I291Stop-Fwd 
GCCTTCGTAGAACGTGGTGGTTAGTACGATTGGAATAAATCTTCC 
I281Stop-Rev 
GGAAGATTTATTCCAATCGTACTAACCACCACGTTCTACGAAGGC 
G289Y+G290Stop + ∆1-10 (Used plasmid of G290Stop+∆1-10 to make G289Y mutation) 
G289Y+G290Stop-Fwd 
ATGAAGAAGCCTTCGTAGAACGTTATTGAATCTACGATTGGAATAAATCTT 
G289Y+G290Stop-Rev 
AAGATTTATTCCAATCGTAGATTCAATAACGTTCTACGAAGGCTTCTTCAT 
G289Y+I291Stop + ∆1-10 (Used plasmid of I291Stop+∆1-10 to make G289Y mutation) 
G289Y- I291Stop-Fwd 
GAAGAAGCCTTCGTAGAACGTTATGGTTAGTACGATTGGAATAAATC 
G289Y- I291Stop-Rev 
GATTTATTCCAATCGTACTAACCATAACGTTCTACGAAGGCTTCTTC 
Homo Sapiens 
>Hsa-Non-His-tag 
MVLRGPDETK EEEEDPPLPT TPTSVNYHFT RQCNYKCGFC FHTAKTSFVL 
PLEEAKRGLL LLKEAGMEKI NFSGGEPFLQ DRGEYLGKLV RFCKVELRLP 
SVSIVSNGSL IRERWFQNYG EYLDILAISC DSFDEEVNVL IGRGQGKKNH 
VENLQKLRRW CRDYRVAFKI NSVINRFNVE EDMTEQIKAL NPVRWKVFQC 
LLIEGENCGE DALREAERFV IGDEEFERFL ERHKEVSCLV PESNQKMKDS 
YLILDEYMRF LNCRKGRKDP SKSILDVGVE EAIKFSGFDE KMFLKRGGKY 
IWSKADLKLD W* 
>Hsa-His-tag 
LVLRGPDETK EEEEDPPLPT TPTSVNYHFT RQCNYKCGFC FHTAKTSFVL 
PLEEAKRGLL LLKEAGMEKI NFSGGEPFLQ DRGEYLGKLV RFCKVELRLP 
SVSIVSNGSL IRERWFQNYG EYLDILAISC DSFDEEVNVL IGRGQGKKNH 
VENLQKLRRW CRDYRVAFKI NSVINRFNVE EDMTEQIKAL NPVRWKVFQC 
LLIEGENCGE DALREAERFV IGDEEFERFL ERHKEVSCLV PESNQKMKDS 
YLILDEYMRF LNCRKGRKDP SKSILDVGVE EAIKFSGFDE KMFLKRGGKY 
IWSKADLKLD W* 
gBlock for his-tag human viperin from thesis 
>Viperin_Hsa_51-361_Thesis_BamHI_NotI 
GCGATGGATCCGCTA GTG  CTG CGC GGT CCG GAT GAA ACC AAA GAA GAA 
GAA GAA GAT CCG CCG CTG CCG ACC ACG CCG ACC TCA GTT AAC TAT CAT 
TTT ACG CGT CAG TGT AAT TAC AAA TGC GGC TTT TGT TTC CAC ACC GCG 
Table 6.2. (cont.) 
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AAA ACG TCG TTC GTG CTG CCG CTG GAA GAA GCG AAA CGT GGT CTG CTG 
CTG CTG AAA GAA GCC GGC ATG GAA AAA ATT AAC TTT TCA GGC GGT GAA 
CCG TTC CTG CAG GAT CGC GGT GAA TAT CTG GGC AAA CTG GTT CGT TTT 
TGC AAA GTC GAA CTG CGC CTG CCG AGC GTT TCT ATT GTC TCA AAC GGT 
TCG CTG ATC CGT GAA CGC TGG TTT CAA AAT TAT GGC GAA TAC CTG GAT 
ATT CTG GCC ATC AGC TGC GAT TCT TTC GAC GAA GAA GTG AAC GTT CTG 
ATC GGC CGC GGT CAG GGC AAG AAA AAC CAT GTC GAA AAT CTG CAA AAA 
CTG CGT CGC TGG TGT CGT GAT TAC CGC GTT GCA TTC AAA ATC AAC TCC 
GTG ATC AAC CGT TTC AAT GTT GAA GAA GAC ATG ACC GAA CAG ATT AAA 
GCT CTG AAC CCG GTG CGC TGG AAA GTT TTT CAA TGC CTG CTG ATC GAA 
GGT GAA AAT TGT GGC GAA GAT GCG CTG CGT GAA GCC GAA CGC TTC GTG 
ATT GGT GAC GAA GAA TTT GAA CGT TTC CTG GAA CGC CAC AAA GAA GTC 
AGT TGC CTG GTG CCG GAA TCC AAC CAG AAA ATG AAA GAT AGC TAT CTG 
ATC CTG GAC GAA TAC ATG CGT TTT CTG AAT TGT CGT AAA GGC CGC AAA 
GAT CCG AGT AAA TCC ATT CTG GAC GTC GGT GTG GAA GAA GCG ATC AAA 
TTT TCT GGC TTC GAT GAA AAA ATG TTC CTG AAA CGT GGT GGC AAA TAC 
ATC TGG AGC AAA GCC GAC CTG AAA CTG GAT TGG TGAGCGGCCGCATCGC 
Primers for cloning Non-His-tag version: 
Vip_Hsa_51-361_Thesis_NH_XbaI_Fwd 
GCGTAC TCTAGA AATAATTTTGTTTAACTTTAAGAAGGAGATATACC 
ATGGTGCTGCGCGGTCCG 
Vip_Hsa_51-361_Thesis_NH_NotI_Rev 
GCGAG GCGGCCGC TCACCAATCCAGTTTCAGGTC 
Table 6.2. gBlock sequences and primers for viperin constructs with soluble protein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table. 6.2. (cont.) 
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CHAPTER 7: CONCLUSION AND FUTURE DIRECTIONS 
 
7.1. Conclusion 
  
Of the six subunits in the Elongator complex, Elp3 is the most highly conserved and is 
present in almost all archaea, some bacteria and a few viruses. Archaea and bacteria with Elp3 
(and not Elp1-2 and Elp4-6) do not have homologs of the MnmE-MnmG complex, which is 
responsible for the wobble uridine modification found in bacterial tRNAs. This, along with the 
fact that the Elongator complex was mostly observed in the cytoplasm, suggests that archaea and 
bacteria with Elp3 are likely to have the same tRNA wobble uridine modification as cytoplasmic 
tRNAs in eukaryotes. Archaeal Elp3 selectively binds certain tRNAs and can form a stable 
complex. Elp3 alone is able to catalyze the tRNA wobble uridine modification by the addition of 
a carboxymethyl (cm) group at C5 of U34.  The modification reaction proceeds via a radical SAM 
mechanism using acetyl-CoA as the donor, where the 5’-dA• abstracts a hydrogen atom from the 
methyl group of acetyl-CoA and association of tRNA is required for generation of 5’-dA•. A study 
of the in vivo modifications revealed two potentially new modifications in archaeal tRNAs 
corresponding to a molecular weight of 549 Da and 454 kDa. This may be the result of a secondary 
reaction on cm5U. The structure revealed a L-shaped N-terminal domain which may be involved 
in binding tRNA with the anticodon loop and co-factors entering the channel to perform the 
modification. 
Viperin is an interferon induced protein, which is also a radical SAM enzyme. It has been 
established that viperin inhibits a broad range of viruses; however, the molecular mechanism 
remains unknown. Biochemical and structural studies demonstrate that viperin catalyzes a radical 
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reaction on IPP, one of the key intermediates of the mevalonate pathway, producing a new 
compound, AIPP. Thus, the antiviral activity appears to result from the interference of the 
mevalonate pathway, which is important for several cellular functions including cholesterol 
biosynthesis and protein prenylation. 
 
7.2. Future directions 
Further investigation of tRNA U34 modification in vivo 
The six Elp3 depicted in Fig 7.1 represent a broad spectrum of Elp3 depicted in the 
Sequence Similarity Network (Fig. 2.3). It is apparent that the N-terminal domain of Elp3 is the 
least conserved. An ideal list of organisms to further characterize the U34 modification in vivo 
would involve a euryarchaota, crenarchaeota, bacteria from Cluster 1 and bacteria from Cluster 3 
(Fig. 2.2). Currently, it is not feasible to obtain sufficient cells of the bacteria in Cluster 1. We have 
collaborations with the Whitman (University of Georgia), Grogan (University of Cincinnati) and 
Wilson (University of Illinois at Urbana-Champaign) laboratories, who will assist us in growing 
cells for Methanococcus maripaludis, Methanocaldococcus infernus, Sulfolobus acidocaldarius 
and Atopobium vaginae for further characterization of tRNAs. Future plans include isolating and 
analyzing other individual tRNAs including tRNAGln, tRNALys and tRNAGlu. High-resolution MS 
and MS-MS will be performed to identify the chemical structure of the two new modifications. 
Our collaborators will also assist in generating Elp3 deletion mutants in Methanococcus 
maripaludis and Sulfolobus acidocaldarius to understand growth properties and investigate 
biological roles of Elp3 in archaea. 
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In analyzing the organisms on the sequence similarity network, we identified a small 
number of bacteria (all belonging to the Actinobacteria phylum) which do not have MnmE-MnmG 
or Elp3 genes and we are interested in studying the tRNA modification found in these species.  
 
Further investigation of tRNA U34 modification in vitro 
The SAM domain, the HAT domain and the highly conserved domain connecting the SAM 
and HAT domain are likely essential for catalysis. However, the N-terminal domain may not be 
essential, as suggested by its highly variable N-terminal domain (Fig. 7.1). Future experiments 
include testing the enzymatic activity of various N-terminal truncations of MinElp3. These 
experiments might provide insight into whether the shorter versions of Elp3 are enzymatically 
active.  
 
Further investigation of the Elp3-catalyzed reaction 
To further understand the sequential steps of the Elp3 catalyzed reaction, the roles of the 
other subunits of the Elongator complex will be studied. Future experiments include purifying the 
Elongator complex from yeast and HeLa cells, reconstituting the [4Fe-4S] and assessing the 
enzymatic activity of the complex. If the reaction is successfully reconstituted, the following will 
be studied: (i) Elp1-2 may “cage” Elp3 to prevent the radical from damaging other cellular 
components (ii) Elp1-2 may shield the radical from being quenched by oxygen, or [4Fe-4S] being 
oxidized by oxygen (iii) Elp1-2 may assist Elp3 in selecting the correct tRNA and (iv) Elp4-5 may 
help load the tRNA substrate or unload the tRNA product to increase the efficiency of catalysis.   
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Further structural studies on Elp3 
The structure of Elp3 will be pursued by cloning and purifying Elp3 from additional 
organisms. In addition, other in vitro transcribed U34 containing tRNAs will be used to create 
Elp3-tRNA complexes for crystallization. Also, protein can be purified inside the anaerobic 
chamber to crystallize the protein with [4Fe-4S]. Also, the cluster can be chemically or 
enzymatically reconstituted inside the chamber to allow for higher occupancy.     
 
Further studies on the viperin-catalyzed reaction 
As mentioned in Chapter 5, the efficiency of the reaction performed by HsaViperin-∆50 
has a low Reaction Yield. The full length human viperin cannot be used to optimize the reaction 
as is not soluble in Escherichia coli. The efficiency of the reaction may be improved by using 1% 
detergent. Also, if CIAO1 (a probable [4Fe-4S] assembly protein) is shown to associate with 
viperin, a reaction will be performed with the complex. Lastly, the in vivo reaction will be 
mimicked using the NanoDisc, a synthetic membrane system (137).   
 Some details of the viperin-catalyzed reaction are unresolved. Future studies will focus on 
understanding the source of the hydrogen that terminates the radical reaction to produce AIPP. 
Also, future studies will determine the possible cause of product inhibition and the source of the 
in vivo electron donor.  The molecular mechanism of viperin will also be investigated in vivo and 
the potential antiviral activity of AIPP will be tested with several viruses.  
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Further structural studies on viperin 
 The crystal structure of TviViperin-∆10 with the intact [4Fe-4S] will be pursued by 
purifying and crystallizing the protein inside the anaerobic chamber. Also, future studies will focus 
on obtaining the crystal structure of viperin with SAM, IPP and AIPP.  
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7.3. Figures 
 
Fig 7.1. Schematic view of six Elp3 representing three domains of life. Also shown is the 
difference in spacing between the first and the second cysteines of the conserved motif that ligates 
[4Fe-4S].  Hsa, Homo sapiens; Sce, S. cerevisiae; Min, Methanocaldococcus infernus; Sac, 
Sulfolobus acidocaldarius; Det, Dehalococcoides ethenogenes; Ava, Atopobium vaginae.  Elp3 
from Methanococcus maripaludis, the organism for genetic studies, is very similar to MinElp3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Euryarcheota 
Crenarchaeota 
Cluster 1 
Cluster 2 
Cluster 3 
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